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The conjugation of poly(ethylene glycol) (PEG) to peptides is known to increase 
serum stability of peptides and long polydisperse PEGs have been used for decades as a 
strategy to improve pharmacokinetic profiles of protein therapeutics. However, the 
effects of PEGylation on the conformational stability and protease resistance of peptides 
will unpredictably vary depending on 1) site(s) of PEGylation, 2) conjugation strategy, 3) 
chain length, as well as 4) chain branching. Site-specific PEGylation of peptides requires 
the use of cumbersome protecting groups and, when performed at lysines, often 
transforms the amine into an amide. To facilitate both fundamental and applied studies of 
peptide PEGylation, the current toolbox needs to be expanded.  
Analogues of glutamine and lysine incorporating a linear PEG or branched di- and 
triPEG side chains have been synthesized using several synthetic approaches. 
Additionally, biotin and fluorescein have been covalently attached to the N-position of 
lysine that is bifunctionalized with a single linear N-PEG chain. Additionally, many of 
the synthesized PEG amino acids have been site-specifically incorporated into 
biologically relevant peptide sequences.  
These PEG-amino acid monomers can be directly incorporated into solid phase 
peptide synthesis to study their effects on peptide folding energetics (conformational 
stability) and ultimately to further enhance pharmacokinetic properties of PEGylated 
peptide drugs. The bulkier nature of the novel branched PEG amino acids can potentially 
be used to help solubility in aqueous environments or repel macromolecules from a 
iii  
peptide cleavage site. Additionally, this strategy should be useful for the generation of 
single- and multi-site selectively PEGylated peptides for therapeutic applications.  
Due to a growing interest in peptidomimetics for their potential applications in the 
pharmaceutical industry, two classes of peptidomimetics were investigated: Freidinger 
lactams and peptoids. Freidinger lactams were originally designed as a conformationally 
constrained dipeptide that could be used to lock a synthetic peptide into a bioactive 
conformation; however, the current synthetic approach is typically low yielding and 
limits functionalization. An improved synthetic route to Freidinger lactams was 
developed that allows for chirality off the N position. Peptoids, unlike peptides, have 
side chains appended to the backbone nitrogen instead of the -carbon; a structural 
change that makes them more stable to proteolysis. A small library of antimicrobial 
peptoids with varying aliphatic, cationic, and aromatic side chains have been designed 
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PEPTIDES AS THERAPEUTICS 
 
The role of natural peptides in the body. 
Over 7000 natural peptides have been identified thus far in the human body—
exhibiting a wide array of biological activities. The major role of peptides within biological 
systems is as signaling molecules; typically binding to G protein-coupled receptors (GPCR’s) 
and triggering a cascade of reactions. Some of the broad classifications of these peptides 
include hormones, metabolic peptides, and antimicrobial peptides.  
Early research on small-molecule and protein hormones, such as testosterone and 
growth hormone, respectively, sparked knowledge of the endocrine system that progressively 
led to studies identifying peptide hormones. The pituitary gland within the brain was 
correctly thought to be highly important to hormone production. A major role of the pituitary 
gland is to regulate the amount of hormones within the body: ensuring that not too much (or 
too little) is in circulation at a time. By the 1980’s it was understood that peptide hormones 
are very important to human physiology.1  
Peptide hormones (Figure 1.1), such as glucagon and growth hormone-releasing 
hormone, are secreted primarily from various organs within the neuroendocrine system, but 
can also be secreted by the heart and gastrointestinal tract. The peptide hormones are released 
only in response to some extracellular stimuli; for a hormone, such as insulin, the stimulus is 
a high blood-glucose level. Upon their release into the plasma, these peptide hormones allow 




contrast to steroid-type hormones that are more lipid soluble and act on intracellular targets, 
peptide hormones typically act on cell surfaces.  
Within this group of peptide hormones are subclasses, such as incretin hormones like 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) that 
stimulate a decrease in blood glucose in response to the biological environment. Additionally, 
the human body has peptide hormones like ghrelin to help regulate our appetite. Ghrelin is 
considered “the hunger hormone” because it makes us feel hungry, while GLP-1 has 
opposingly demonstrated the ability to decrease gastric emptying and make us feel full. 
Peptide hormones, like atrial and brain natriuretic peptides, have major roles in 
cardiovascular health as well as metabolism regulation.2 Similarly, a peptide such as 
vasopressin, or antidiuretic hormone, has shown versatile physiological effects with not only 
its cardiovascular role of increasing vasoconstriction, but also in the regulation of water 
retention via acting on the kidney.  
Antimicrobial peptides (AMPs), increasingly called host defense peptides (HDPs) due 
to their immunomodulatory effects, are an important component of our human immune 
system.3 Typically, AMP/HDPs are cationic and exist primarily in two major classes: 
defensins (cysteine-rich; ß-sheet) and cathelicidins (non-cysteine-rich; a -helix).4 These 
natural peptides have evolved in vivo to offer broad-spectrum protection against microbial 
infection.5, 6 With antimicrobial agents, there is always the possibility of bacteria developing 
resistance; AMPs are no exception.7  
Nature has optimized peptides to exhibit a high selectivity for their native receptors, 
which leads to less adverse side reactions. With over 600 proteases existing in the human 




tissues within biological systems and their degradation pathways are well understood.8 In 
many ways, beyond their high selectivity for native receptors, peptides are within a 
goldilocks zone between small molecule and protein therapeutics. 
 
Figure 1.1. Select examples of natural peptide hormones within the body.  
 
Where peptide therapeutics fit in the spectrum between small molecules and proteins. 
 
In the late 19th century and very early 20th century, diabetes was being recognized as a 
devastating killer of the population with no treatment options in sight. Around 1920 it was 
suggested that diabetes resulted from a lack of a pancreatic secretion/hormone. Dr. Frederick 
Banting, a physician, and his lab assistant Charles Best, a medical student, surgically 




hormone from pancreatic islets without destroying the peptide. This work led them to the 
isolation and discovery of insulin in 1921. In 1922, Leonard Thompson—on the brink of 
death—was recorded as the first individual to receive an insulin injection for the successful 
treatment of type-I diabetes. Banting went on to receive the 1923 Nobel Prize in Physiology 
or Medicine for his discovery. The turnaround time between isolation of insulin and the first 
patient treatment was incredibly fast and is no longer representative of the time to market 
found in today’s drug discovery pipeline. 
The discovery and medical usage of insulin was an early example of the power 
peptides could have in the treatment of illness. Standard conventions identify peptides as 
amino acids linked through amide bonds between 2 and 100 residues in length before being 
considered a protein. However, the pharmaceutical industry blurs the lines even further by 
classifying peptides under ~1300 Daltons (Da) as small molecules; gonadorelin (FactrelTM) is 
one such peptide therapeutic that falls in that category. Alternatively, protein therapeutics are 
typically classified as having molecular weights over 10,000 Da. Peptides usually violate 
Lipinski’s rule of five which predicts oral bioavailability;9 While the rule of five was derived 
for oral availability via passive diffusion across the intestinal membranes, peptides are 
usually orally not bioavailable due to proteolytic digestion in the gut. Despite this handicap 
they are definitely a highly sought-after drug class for targeted therapies with minimal side 
effects. 
The current global peptide therapeutic market is ~$19 billion (US) as of 2015 and is 
expected to grow to over $23 billion (US) by 2020.10 To date, 63 peptide drugs have been US 
Food and Drug Administration (FDA) approved and with over 700 clinical trials currently 




years to come. Nevertheless, amongst large pharmaceutical companies, peptide molecules are 
still the minority of drugs being developed.  
Peptides of varying length have found usefulness within diverse therapeutic 
indications from osteoporosis (teriparatide) to cancer (degarelix) and even type-II diabetes 
(liraglutide) and obesity.11 Because of high specificity to their native receptors due to their 
high surface area, peptides exhibit minimal off-target effects that would traditionally produce 
side effects in patients. Given the increasing concerns about toxicity (off-target effects) and 
drug-drug interactions in the pharmaceutical industry, coupled with the higher relative costs 
of producting protein therapeutics that also inherently mitigate these concerns, one would 
expect peptide therapeutics to grow for the forseeable future. 
Short natural peptides like oxytocin and vancomycin (a glycopeptide) are approved 
for usage in various indications, such as labor induction and the treatment of infection, 
respectively. GLP-1 analogues continue to exert a dominance within the type-II diabetes 
treatment market with brands such as exenatide (BydureonTM) and liraglutide (VictozaTM). 
Additonally, a 32-amino acid peptide, Nesiritide, is used for the treatment of congestive heart 
failure.  
It has been known for over a decade that there are peptides able to trigger cellular 
apoptosis through caspase activation.12, 13 Research in the area of aptoptosis is associated with 
a growing number of human diseases such as cancer, neurodegenerative disease and 
autoimmune disorders. Short peptides such as Leuprolide have been approved for the 
treatment of prostate cancer.  
Fields such as Alzheimers research with amyloid- peptides—disruption of plaque 




challenge,14, 15 with notable phase III clinical trials in 2016 of Aß plaque removal agents, such 
as Eli Lilly’s Solanezumab, that successfully cleared plaques but did not improve function.16 
There are, however, some FDA-approved small-molecule drugs for the treatment of 
symptoms, such as rivastigmine (ExelonTM) and memantine (NamendaTM).17   
Natural peptides have some very noteworthy benefits when it comes to their usage as 
therapeutics. Amongst these benefits, they have a potentially improved safety margin, in 
addition to potentially higher and more efficacious dosing. Therapeutics are rated in 
accordance with their safety margin—a measure of the difference between the minimum 
toxic dosage and minimum therapeutic dosage of a drug.18 
A majority of the biologically relevant protein-protein interactions occur within the cell as 
opposed to outside of the cell (or on the cell surface). However, current strategies involving 
small molecules or antibodies are not equipped to handle these intracellular interactions. In 
the late 1980’s, it was discovered that certain proteins could cross the cellular membrane and 
subsequently, that only a portion of the protein was necessary for crossing the membrane.19, 
20, 21 It is known that cell permeability falls off at higher molecular weights.22, 23 So, large 
molecules, such as proteins, have encountered difficulties when it comes to crossing the 
cellular membrane, where potential drug targets may reside. Therefore, researchers are 
looking into the possibility of targeted delivery through conjugation of small molecules and 
biologics with cell-penetrating peptides (CPP). In order for this strategy to work, the 
cytostolic delivery efficiency is a metric that needs to be improved. If a CPP has low delivery 
efficiency, then large dosages must be used to get enough of the drug into the cell. Large 
dosages, however, tend to lead to increased toxicity. Some of the earliest examples showed 




into intracellular space has been explored using a variety of strategies in order to optimize 
peptides for disrupting protein-protein interactions.24  
Therefore, even though peptides may offer advantages where their protein and small 
molecule counterparts have limitations, the characteristic shortcomings of natural peptides 
need to be overcome before they can be useful as therapeutic agents. However, exceptions do 
occur as in the case of corticotropin and, formerly, insulin.  
  
The limitations of peptides as therapeutics. 
Peptides (i.e. mainly linear peptides) have some notable shortcomings when it comes 
to their potential usage as therapeutics.25 Economically, peptides generally have higher costs 
associated with their production compared to small molecules. For peptides synthesized 
through biological methods, the manufacturing process is more complex, and thus more 
expensive, than a chemical synthesis production.26 For example, the production cost of a 500 
Da molecular weight small-molecule is 10-fold lower than that of a 5000 Da peptide.27 
However, for smaller peptides, the cost should be more on par with that of small molecules. 
The solid-phase synthesis of batch amounts of peptides is faster and cheaper than the 
recombinant methods used for some longer sequences especially when economy of scale is 
taken into consideration; yielding the ability to reduce production costs to < $1 (USD) per 
gram per amino acid residue.27, 28, 29 Furthermore, peptides obtained from SPPS have better 
purity profiles than those from recombinant methods.30  
Most peptides tend to exhibit poor metabolic stability, membrane permeability, and oral 
bioavailability. A notable exclusion to these downfalls is the peptide therapeutic enfuvirtide 




and an impressive 3.8-hour biological half-life. The half-life of many native peptides is on the 
order of minutes in blood. The poor stability of peptides to native proteases and peptidases 
leads to inactivation as well as rapid clearance—typically, requiring constant dosing for 
beneficial pharmaceutical effects. The practical effectiveness of constant dosing relys heavily 
on patient compliance—the ability of the patient to follow the advice of a medical 
professional. Realistically, the frequent dosings necessary with most peptide drugs often lead 
to low patient compliance. Peptide therapeutics are usually injected with only a few orally 
available peptides to date, such as cyclosporine (NeoralTM) and desmopressin (MiniriniTM). 
The route of administration is known to have a significant effect on the pharmacokinetic and 
pharmacodynamic profile of peptides.31 An increase in the availability of orally administered 
peptide therapies is a highly sought-after goal amongst researchers in the field because it 
would lead to improved patient compliance. However, due to the charge and polarity of 
peptides, they tend to exhibit low permeability across gut membranes. Companies, such as 
Protagonist Therapeutics, are aiming to develop oral peptide therapeutics for gastrointestinal 
disorders and diseases—they currently have one peptide entering phase IIb trials and another 
oral candidate entering phase I.  
Small molecule therapeutics are typically favored when a binding pocket is targeted 
for (de)activation deep within a protein whereas biologics are better for the targeting and 
disruption of protein-protein interactions.32, 33 Peptides are preferred when traditional small 
molecule approaches fail to produce a successful clinical candidate for a particular 
therapeutic indication. For reasons such as those mentioned, peptides are ripe to fill a void 





A major concern in the peptide therapeutic area is the possibility of peptide 
immunogenicity—the ability of peptides to provoke unwanted immune responses. There has 
been debatable views on assessing a products immunogenicity which has led to nonuniform 
assessements and descriptions; however recent effort have attempted to standardize the type 
of data collection necessary to report on immunogenicity of products.34 If there remains a 
perception of immunogenicity amongst pharma/biotech investors, then the full potential of 
peptide therapeutics won’t be realized. There is, however, potential for epitopes to be 
chemically attached to peptides for usage as vaccines.35  
The growth of cardiovascular and metabolic diseases is likely to induce a rise in 
peptide therapeutic research due to high overlap with natural peptide hormone involvement in 
the regulation of these biological systems. Additionally, peptide therapeutics are increasingly 
being studied for their ability to treat gastrointestinal diseases and disorders, such as the 
recent (2012) FDA approval of linaclotide (LinzessTM), a 14-amino acid peptide guanylate 
cyclase 2C agonist.36, 37 Various technological advances over the past decades have renewed 
interest in the usage of peptides as potential pharmaceutical agents.  
 
Efforts to overcome peptide limitations. 
The challenges to using peptides as therapeutics can be overcome through various 
chemical modification strategies such as (but not limited to) half-life extension (HLE) 
strategies.38 Some common peptide HLE strategies include cyclization, PEGylation (Figure 
1.2), O-glycosylation (Figure 1.2), and backbone modifications (e.g., D-amino acids, N-
methylation, etc.). The HLE strategies are extremely important, in the case of peptides versus 




size.39 The discussion below focuses on chemical modifications at the expense of other valid 
and successful HLE strategies such as formulation development.  
 
Figure 1.2. General structures for common half-life extension strategies; PEGylation, 
glycosylation, and lipidation. 
 
Direct chemical modification (post-synthetic) strategies happen later in the peptide 
therapeutic optimization process, which can often lead to a reduction in potency for lead 
compounds; sending researchers back to the proverbial square one. Selective glycosylation—
the addition of saccharide units—is one such strategy that has been demonstrated on 
interferon -1a to improve various pharmacologically relevant parameters such as half-life, 
solubility, and stability.40 This strategy capitalizes on a method which is thought to be a 
major route of protein elimination from circulation, as well as the importance of sugars in 
various cellular processes.  
Another strategy that employs the conjugation of a known polymeric unit is selective 
PEGylation. PEGylation refers to the attachment of polyethylene glycol (PEG) units to a 
target molecule. These PEG units typically exist as large polymer chains and have found 




to their water soluble, hydro- and lipophilic, nontoxic nature. Lysine residues are by far 
amongst the most PEGylated site on peptides, however this can typically reduce efficacy; 
especially if the original lysine was part of a salt-bridge, binding pocket, or active site. As an 
alternative, the site-specific, long-chain PEGylation of glutamine has been achieved 
successfully on a range of peptides (and proteins) by several groups.41, 42, 43, 44 Recent 
research has identified that a non-neglible percentage of healthy individuals likely have some 
antibodies to PEG, which would effectively diminish the effectiveness of any PEGylated 
therapeutics used on these individuals.45, 46 However, there is also research that suggests these 
anti-PEG antibodies bind to larger PEGs with higher affinity than smaller ones.47 It is also 
unclear how effectively the anti-PEG antibodies recognize and bind to PEG chains that are 
terminated in hydroxyls versus methoxy, as well as the antibody’s ability to distinguish 
between linear versus branched PEG chain modifications. This suggests that peptide 
PEGylation with short-chains could be an effective future strategy for consideration in the 
peptide therapeutic arena.  
For the pharmaceutical industry to minimize financial risks associated with failed 
drug candidates late in the development pipeline it is crucial to move certain modification 
strategies and testing to earlier in the drug development process. The incorporation of 
unnatural amino acids directly into SPPS procedures is a more facile and straightforward 
modification strategy than post-SPPS derivitization. This pre-synthetic modification method 
has allowed researchers to introduce various functionalities and modifications such as D-
amino acids, N-methylated backbones, lipidation (Figure 1.2), alkene side-chains for peptide 




Peptide stapling is used to stabilize secondary structure and improve protease 
resistance, yet there have been no clinically successful candidates with this modification. 
Recent studies out of MIT have introduced a N-arylation method capable of macrocyclizing 
unprotected peptides; leading to improved proteolytic stability and improved binding 
affinity.48, 49, 50, 51 Strategies like N-methylation/alkylation and D-amino acid incorporation 
are often used in combination with other strategies in order to achieve the maximum 
beneficial effects, such as in the widely used cyclosporine A and recently approved 
etelcalcetide (ParsabivTM, Figure 1.3). Sometimes, however, swapping out L-amino acids for 
their D- counterparts can cause local kinks in structure which then affect native activity. 
Lipid conjugation is one practical approach that has circumvented some of the delivery 
issues associated with unfavorable peptide pharmacokinetics. The rationale for this approach 
is that the lipid chain increases the association with albumin, which gives the therapeutic 
agent increased protection from blood-circulating peptidases and proteases. This strategy has 
led to two-lipid-peptide conjugates currently on the market; recombinant insulin detemir 
(LevemirTM) and liraglutide (VictozaTM), a blockbuster peptide drug. Only the latter is formed 
through direct chemical modification with a C16 fatty acid chain after expression of 
recombinant DNA in Saccharomyces cerevisiae. The C14 fatty acid chain of insulin detemir 
is installed at a lysine residue during its complete synthesis within yeast cells (all insulins are 













































































































































































































Figure 1.3. Select examples of strategies to overcome limitations of peptide therapeutics.  
 
Cyclic Peptides have proven to be a great strategy for half-life extension of short 
peptide sequences such as octreotide (SandostatinTM) and lanreotide (SomatulineTM), both of 
which are long-acting analogs of somatostatin. As is the case with linaclotide, the 
incorporation of multiple disulfide bonds has demonstrated the ability to improve metabolic 
resistance. Research into this area of multiple disulfide bonds can be traced back to the work 
of David J. Craik and coworkers for their late 20th century work on plant peptides known as 
cyclotides; especially kalata B1.53, 54 Despite over whelming skepticism in the pharmaceutical 




motif were highly stable to extreme conditions.55 In the traditional fashion of scientific 
progress, Craik et al. built their work on the accomplishments of scientific predecessors; 
namely, Lorents Gran who originally discovered and named kalata B1 without any structural 
elucidation.56, 57 Spawning from these early discoveries, pharmaceutical researchers 
worldwide have gained increasing interest in trying to modify these (and other) cyclic peptide 
structures in order to overcome stability limitations. Alanine scans and lysine scans have been 
investigated to identify potential sites important for bioactivity as well as for optimization.58, 
59 The chemical synthesis of these cysteine knot motifs has been investigated with current 
SPPS technology and other strategies,60, 61, 62, 63, 64, 65, 66, 67, 68 but promising biological 
synthesis approaches have also been developed.69, 70, 71, 72 Cyclotides have a diverse array of 
biological activities from antimicrobial to antitumor, which could lend inspiration to current 
and future research within the peptide therapeutics community.73  
Ziconotide (PrialtTM, Figure 1.3), a conotoxin derived from a cone snail (Conus 
Magnus), is similar to cyclotides such as kalata B1 in that it has multiple cysteine bridges. 
This particular cyclic peptide has a biological half-life of several hours compared to the 
typical minutes of uncyclized peptides. Cyclosporin (Figure 1.3) is another cyclic peptide 
that is approved for multiple indications, however it’s backbone is also N-methylated. 
Research has also suggested that ester bonds in the backbone of cyclic peptides, such as 
jasplankinolide, are stable to protease resistance.74  Stereochemistry of the side-chains on 
peptide macrocycles is also known to affect physiochemical properties like cellular 
permeability.  
More recently, work in groups such as the Pei laboratory has combined strategies of 




efficiency.75, 76, 77 His group has demonstrated the ability for cyclic CPPs to deliver small 
molecule cargos as well as proteins and short peptides as well.75, 76  
The attachment of PEG to biologics has been well studied in recent decades for its ability 
to improve the pharmacologic profile of therapeutically relevant biologic compounds. 
PEGylated biologics account for 17 FDA approvals to date, representing a mature technology 
for overcoming various peptide limitations. The PEG molecule itself is generally regarded as 
safe by the FDA. PEGylated amino acid monomers have been synthesized and reported in the 
literature and allow for easy incorporation to SPPS.78 Joshua Price and coworkers 
significantly advanced the understanding of beneficial effects of short-chain PEGylation of 
peptides. Studies on their model peptide showed that PEGylation thermally stabilized 
conformation better than N-glycosylation and that the increased conformational stability leads 
to higher proteolytic stability.79 Thus showing that conformational stability could be a 
predictive trait for researchers to screen for in efforts to overcome peptide limitations with 
PEGylation. Subsequently, it was elucidated that 3- to 4-ether linkage PEGs are the 
minimally effective length for achieving conformational stability.80 Not only was it observed 
that optimal PEG positioning within a peptide was important, but conjugation strategy and 
branching also played a role in affecting PEG benefits.79, 81 Evolution of this technique to 
more amino acid side chains, such as serine, could allow for the easy scanning of PEGylation 
benefits at various peptide sites; giving rise to potential PEG-scans analogous to alanine 
scans which produce analogs of peptides where residues are replaced by alanines to identify 
which side chains are necessary for activity. 
Peptide-drug conjugates are a method for introducing multiple functionalities within the 




whereas another molecule is toxic to a cell so bridging the two—through a linker molecule—
yields a molecule with potentially synergistic effects. These conjugates have found usefulness 
as targeted delivery systems82 for research areas such as targeted tumor therapy.48  
Octreotide-doxorubicin (Figure 1.3) is one such conjugate for the tumor-targeted delivery.83  
A future research area for peptide therapeutics could likely be with bicyclic peptides—a 
currently underdeveloped class that displays potential in the form of very high affinity, 
relatively small size (1.5-2 kDa), and easy tunability.84, 85, 86 The bicyclic peptides, as a 
platform, have a lot of potential for multiple indications although most research at the 
moment is been directed towards tumor-targeting.87, 88, 89  Bicyclic peptides have even 
displayed the ability to interrupt protein-protein interactions.90   
 
Conclusion 
In summary, the usage of peptides as therapeutics is a market full of growth potential.  
Historically, peptides have flown under the radar in terms of therapeutic applications, but as 
technology has improved, peptide limitations are becoming more manageable. Owing to their 
great receptor specificity and binding affinity, peptide therapeutics will continue to gain 
growing importance within the pharmaceutical industry; especially as human life expectancy 
increases and individuals are taking progressively more medications for chronic illnesses.  
There is no one best peptide modification strategy that will overcome the issues associated 
with using peptides as therapeutics, but a mixture of strategies could lead to improved clinical 
outcomes for drug developers. Yet, for the peptide therapeutic market to be more effectively 
mined: 1) new scaffolds need to be elucidated from natural sources, 2) the threat of peptide 
immunogenicity needs to be addressed, 3) chemical modification strategies need to be 
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SYNTHESIS OF LINEAR AND BRANCHED PEGYLATED GLUTAMINE BUILDING 




 Peptides have great potential as therapeutics because of their high selectivity for 
native receptors.1, 2 However, peptide therapeutics suffer from short half-lives due to protease 
degradation, poor solubility, and low oral bioavailability.1  
Many techniques such as glycosylation, N-methylation, peptide stapling, D-amino 
acid incorporation, and others, have been used to mitigate the pitfalls of using peptide 
therapeutics,3, 4, 5, 6 but these efforts have found limited clinical success.  
The poly(ethylene glycol) polymer has demonstrated numerous benefits when 
conjugated to peptides and proteins, including increased half-life due to protease stability and 
improved solubility.7 The PEG molecule is generally regarded as safe by the FDA and 
conjugation of PEG to proteins has resulted in 15 FDA approvals to date. 
There is growing debate about the potential disadvanages of peptide PEGylation,8, 9, 10, 
11 but the concerns focus about long, polydisperse PEGs instead of short, monodisperse PEGs 
as utilized here. 
Peptides are typically PEGylated at the N-terminus or on a lysine or cysteine 




ivDde).13 Deprotection of the residue of interest, after peptide synthesis, liberates the desired 
modification site where reactivity can be directed specifically through introduction of an 
activated PEG (typically NHS esters). These modifications can have substantial 
consequences on the peptide, such as by replacing the naturally positively charged lysine 
amine side chain with a neutral amide. Unsurprisingly, conjugation strategy has a strong 
impact on the conformational stability of the resulting conjugate.14 Therefore, a post-
synthetic modification, which is how PEG is typically attached to peptides, can diminish 
biological activity if not conjugated in an optimal fashion and demonstrates a need to test for 
PEGylation benefits earlier in the drug discovery process. Synthesizing amino acids already 
incorporating short, discrete PEGs would advantageously enable direct incorporation of 
PEGylated amino acids during peptide synthesis and obviate the need for orthogonal 
protecting strategies. A pre-PEGylated amino acid strategy could give rise to a PEG-scan 
capability where each amino acid is systematically replaced by a PEGylated amino acid, 
allowing for a screen of PEGylation benefits from an earlier stage of the lead optimization 
process. 
Site-specific PEGylation of peptides has been achieved by researchers using varying 
methods and has been reviewed by others in the literature.15, 16 The bulk of these PEGylation 
methods involve a post-synthetic peptide modification that specifically targets the N-
terminus, incorporated non-natural amino acid side-chains (e.g. azides, alkynes), or the 
nucleophilic nature of thiols. Short monodisperse PEG attachments to peptides, like 
neuropeptide Y, galanin, GIP, as well as proteins have recently displayed improved 




strategy enables facile incorporation of PEG topologies (e.g. triPEGylated lysine) never 
before attempted. 
The amino acid building block method is the simplist way to incorporate 
modifications into a peptide and has been explored with a variety of side-chain 
modifications.21, 22, 23, 24, 25, 26, 27, 28, 29, 30 While short PEGylated (linear, 4-ether linkages) 
asparagine has been reported previously by others,10, 31 we believe it highly relevant to 
expand the building blocks to glutamine and lysine, as they are amongst the most solvent 
accessible amino acids found in protein structures.32 To this aim, we have adapted a 
straightforward strategy entailing the conversion of commercially available Fmoc-Lys(Boc)-
OH and Fmoc-Glu(OtBu)-OH into PEGylated Fmoc-amino acids suitable for solid-phase 
peptide synthesis (SPPS). Thus, we have developed (1) a scalable strategy for pre-PEGylation 
that does not require orthogonal protecting groups, and (2) Fmoc-protected amino acids with 
unprecedented degrees of branched PEGs. 
Typically, to achieve site-selective PEGylation at glutamine within a peptide 
sequence, transglutaminase would need to be used in the presence of peptide and the desired 
modification with amine functionality (Figure 2.1.1).33 This method has been used to 
specifically PEGylate the GLP-1 (7-36 amide)34 as well as proteins such as apomyoglobin 
(apoMb), α-lactalbumin (α-LA), human growth hormone (hGH), human granulocyte colony-







Scheme 2.1.1. Literature presedent for enzymatic site-selective glutamine side-chain 




The ideal sites for this proposed PEGylation of peptides would be residues that are 
solvent exposed in peptides and if modified will potentially not interfere with the peptides’ 
structure or function. Glutamines (Gln), asparagines (Asn), and lysines (Lys) (Figure 2.1.1) 
are most often found on the solvent exposed portion of peptide drugs and provide 
solubility.32, 37 Since Gln and Asn do not participate in salt bridges or hydrophobic 
interactions, they are ideal for direct PEG modification. Although lys does often participate in 
salt bridges, our proposed PEGylation should not significantly affect its pKa and ability to 
participate in salt bridges. Our proposed PEGylation method is in contrast with using 
orthogonal protecting groups to couple lysines with PEG carboxylic acids, which removes the 
positive charge required for salt bridges.   
Glutamine (Gln)  Asparagine (Asn) Lysine (Lys)
 




Folding of the peptide will have a substantial effect on the amount of protease 
protection that this PEG side chain will provide.  If a peptide has a helical fold, then there is 
potential to have protease protection up to 3 or 4 residues away from the site of PEG 
modification.  Increasing peptide conformational stability through short-chain PEGylation 
has demonstrated that it can be an effective strategy for increasing proteolytic stability.31, 38 
Additionally, short-chain PEG branching on a peptide has shown to be more effective at 
stabilizing peptide conformation as compared to short linear PEG chains.14 Recent molecular 
dynamic simulations support the experimental results by suggesting PEG increases 
conformational stability through shielding of a peptide’s backbone hydrogen bonds.11 
 
MATERIALS AND METHODS 
Chemicals 
All Fmoc-protected amino acids were obtained from Aapptec (Louisville, KY) and 
used without further purification. Triethylene glycol monomethyl ether (TEGME or mTEG) 
obtained from TCI America (Portland, OR). Trifluoroacetic acid, trifluoromethanesulfonic 
anhydride were obtained from Oakwood Chemicals (Estill, SC). 1-Propylphosphonic acid 
cyclic anhydride obtained from Alfa Aesar (Haverhill, MA). N,N’-Diisopropylethyl amine 
and triisopropylethyl amine were obtained from Chem-Impex International (Wood Dale, IL). 
Methanol, dichloromethane, acetone, sodium bicarbonate (NaHCO3) were obtained from 
VWR International (Radnor, PA). Acetonitrile obtained from Sigma-Aldrich (St. Louis, MO). 





NMR. 1H and 13C NMR spectra were collected on a Bruker 500 MHz FT-NMR 
spectrometer. All collected spectra for intermediates and final products can be found in 
Appendix A. 
Peptide Synthesis. Coupling of Amino Acids. The peptides reported here were 
synthesized manually using standard Fmoc-SPPS methods on Rink Amide resin. Rink Amide 
MBHA resin (100 mg) with 0.51 mmol/g loading was swollen in DMF (1 mL, 2 x 1 min) 
with stirring. Resin was deprotecting by stirring with 20% 4-methylpiperidine in DMF (1 mL, 
2 x 1 min). N-Fmoc protected amino acids (4 equiv) were then coupled to resin in DMF in 
the precence of HCTU (16 equiv), 6-Cl-HOBt (8 equiv) and DIEA (16 equiv) for 5 min (2 x). 
Resin was washed extensively with DMF (3 x 1 mL) between reactions. Only the N-termini 
of model -helical peptides (containing i+4 E-K) were acetylated with acetic anhydride, the 
resin was washed with DCM (2 x 1 mL). All peptides were cleaved from the Rink Amide 
resin as peptide amides with a 95:2.5:2.5 trifluoroacetic acid/triisopropyl silane/water 
mixture. 
Coupling of PEGylated Amino Acids. After the desired amino acid couplings had been 
achieved, resin was deprotected with 20% 4-methylpiperidine in DMF (1 mL, 2 x 1 min) and 
washed with DMF (3 x 1 mL). The resin was mixed with the desired PEGylated amino acid 
(4 equiv) in DMF in the presence of HCTU (16 equiv), 6-Cl-HOBt (8 equiv), and DIEA (16 
equiv) for 10 minutes (2 x). After coupling, resin was washed with DMF (3 x 1 mL) followed 
by 20% 4-methylpiperidine in DMF (1 mL, 2 x 1 min). The remainder of the amino acids 




MALDI-MS. MALDI-MS spectra were collected using a Bruker Omniflex MALDI-
TOF mass spectrometer. All collected spectra for small molecule intermediates and final 
products can be found in Appendix A. All collected spectra for peptide products can be found 
in Appendix B. 
HPLC Purification. The peptides were purified by C18 reverse-phased 
chromatography, and peptide identity was confirmed by MALDI-mass spectrometry. The 
peptides were purified on a Shumadzu HPLC instrument equipped with HASIL 100 RP-C18 
5μm column. The column dimensions are 250 x 10 mm. Pore size 80 Å. Purification/analysis 
was done in the following elution sequence― Solvents: A, Acetonitrile (with 0.1% TFA); B, 
H2O (with 0.1% TFA). The solvent gradient used for compound purification was: 0-1 min, 
5% A in B; 1-20 min, 5-95% A in B; 20-23 min, 95% A in B; 23-25 min, 5% A in B at a flow 
rate of 1.0 mL/min. Peptide purity was assessed by analytical C18 reverse-phase 
chromatography using the Shumadzu HPLC system. All collected spectra for peptide 
products can be found in Appendix B. 
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RESULTS AND DISCUSSION 
 
Retrosynthetic Analysis. The proposed synthetic mTEG-glutamine building blocks are 
shown in Figure 2.1.2. The desired mTEG modification for glutamine (and asparagine) 
derivatives would be easily accessible through the amide bond formation of an mTEG-amine and 
the free side-chain carboxylic acid of an α-COOH–protected glutamic acid (Figure 2.1.3). 
PEGylated amines of varying lengths could be synthesized and coupled to the protected glutamic 
acid intermediate by starting with the appropriate, commercially available monomethoxy-PEG-































1 2 3  
Figure 2.1.2.  Synthetic PEG glutamine targets of interest. 1 – mTEG1 glutamine.  2 – 
mTEG2 glutamine. 3 – mTEG3 glutamine.   
 





Chain Length Selection. We decided to use a 3-ether linkage for the initial PEG chain 
attachment. C-C bonds are around 1.5 Å long and a C-O bond is not much different (1.4 Å).  
Having 10 bonds, the equivalent of a 3-ether linkage, should theoretically be able to reach 
between 10-15 Å.  This could interfere with protease binding near neighboring residues no 
matter the peptide folding.  However, if the peptide is folded, protection is possible further away 
from the site of PEGylation.  In an alpha helix, there are 3.4 residues per turn and it is 5 Å from 
one loop in an alpha helix to the next loop so this is the theoretical basis upon which our 
proposed PEG chain length was chosen. 
Additionally, in recent literature, PEG chains of 3-4 ether linkages have demonstrated to 
be the minimally useful length in improving peptide conformational stability and improving 
protease resistance.31 
 
Cost Reduction of Strategy. Other researchers have synthesized a longer PEG Gln 
analog from the -OtBu-protected glutamic acid starting material, but this route isn’t the most 
scalable due to the high costs of starting materials (Figure 2.1.4). Our route would be more 
economically feasible for many researchers especially those who want to make these PEGylated 




Figure 2.1.4. Top – Literature synthetic strategy for monoPEG Fmoc-Gln/Asn. Bottom – Cost 
of starting materials for literature route (left) versus our proposed route (right).  
 
Fmoc-Gln(mTEG)1-OH Synthesis.  PEGylated glutamine, 1, was identified as an initial 
target due to the prevalence of glutamine in many biologically relevant peptides, and the 
proposed retrosynthetic route for amino acid 1 (Scheme 2.1.4) requires an orthogonal protecting 
group. Selection of the appropriate carboxylic acid protecting group is essential in this synthetic 
strategy with the following restraints: (1) The free α-carboxylic acid needs to be protected under 
conditions that will not cleave the other protecting groups; (2) The existing side chain protecting 
groups need to be cleaved without affecting the α-carboxylic acid protecting group under acidic 
hydrolysis (pH < 1); and (3) the α-carboxylic acid protecting group needs to be removed under 
conditions that would not deprotect the N-α-Fmoc or racemize the alpha carbon.  Phenacyl ester 
(OPac) was chosen as a protecting group since it can be installed and removed using orthogonal 
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chemistries without racemizing the alpha-carbon by utilizing Mg, MeOH/DMF, and AcOH.39 
Alternatives choices include using either an allyl ester or 2,2,2-trichloroethyl ester. 
 
The PEG-amine (mTEG-NH2), was synthesized from the inexpensive commercially 
available tris(ethylene glycol)monomethyl ether (Scheme 2.1.2).40, 41 The alcohol was converted 
into a better leaving group by a reaction with methanesulfonyl chloride (MsCl).  A subsequent 
reaction with sodium azide displaced the mesylate with an azide. These reactions have repeatedly 
been performed at >10g scales. A reduction of the azide (mTEG-N3) with lithium aluminum 
hydride (LiAlH4) afforded the desired mTEG-NH2. The intermediates and final product can be 
easily followed by NMR analysis as shown in Figure 2.1.6. 
 
Scheme 2.1.2. Synthesis of 1.   Reagents and conditions: a) Bromoacetophenone, Na2CO3, 
N(Bu)4Br, DCM, r.t., 24-72 hr, 82-95%. b) 3:1 (v/v) TFA:DCM, r.t., 2h, 92%-quant. c) CDI, 
DCM (or dry MeCN), r.t., 4 hr, 65-81%. d) Mg, AcOH, MeOH, DMF, r.t., 90%-quant. or Zn 
dust, acetylacetone, pyridine, EtOAc, 45 oC, 4 hr.  e) MsCl, DIEA, DCM, 0 oC, 2 hr, quant. f) 




There are alternatives to the chosen route, but LiAlH4 reduction of azide was selected as 
most efficient and safest for our purposes. The Mitsunobu reaction wasn’t used to generate the 
azide since (1) it uses azidic acid (HN3) which is explosive, and (2) triphenyl phosphine oxide 
byproduct and unreacted triphenyl phosphine are water insoluble and often chromatography is 
required for the separation of products which is difficult even after chromatography.  
If the mesyl ester was reacted with CN- and then reduced with NaBH4 to avoid azide, this 
path would add an additional carbon atom; however, there is no practical or strategic reason that 
we would not want an extra carbon. It is a plausible alternative route to the amine.  Additionally, 
the use of cyanide comes with its own problems.  If it is used and becomes acidic, forming HCN, 
that’s extremely toxic.  Even though if you have CN- then of course that is not under acidic 
 
Figure 2.1.5. 1H NMR comparison of mTEG intermediates in the synthesis of monoPEGylated 




conditions, but you would have to be very careful with even the waste produced.  The azide is 
potentially explosive and should be worked with cautiously.  A general rule is to have at least 3 
carbons per azide so ours should theoretically not be explosive and has proven to be stable and 
easy to handle. Lithium aluminum hydride is potentially dangerous with fire hazards, but it can 
be managed with careful lab technique and reaction conditions (e.g. THF instead of Et2O).  
In 2000, there was a publication from a group in Italy where an azide reduction that 
utilizes Cobalt (II) chloride and NaBH4 in water was used and that is a potentially safer route that 
holds some promise.42 This route was examined experimentally for its feasibility and practicality 
and forms the monoPEG-amine as observed by NMR analysis (Figure 2.1.7). There is more than 






Figure 2.1.6. Alternative mTEG-amine synthesis route using cobalt (II) chloride42 and NMR 
comparison to product obtained from reduction of mTEG-azide to mTEG-amine using 
LiAlH4.  
 
Another alternative method to obtaining monoPEG-amine from the azide precursor 
without using LiAlH4 could be the Staudinger reduction (shown below, Scheme 2.1.3). The 
azide can also be reduced via Pd-catalyzed hydrogenation conditions. Neither of these two routes 






Scheme 2.1.3. Staudinger reduction mechanism.  
 
The synthesis of intermediates Fmoc-Glu(OtBu)-OPac and Fmoc-Glu(OH)-OPac was 
carried out as shown (Scheme 2.1.2) in >10g scales, and required only optimization of the 
TFA:H2O ratios to ensure full cleavage of the γ-carboxylate t-butyl protection group. Coupling 
of the mTEG-NH2 with Fmoc-Glu(OH)-OPac (Figure 2.1.7) required some screening of the 
coupling reagent to ensure high yields.  The coupling was originally screened using three 
carbodiimides to activate the carboxylic acid: diisopropylcarbodiimide (DIC), 
dicyclohexylcarbodiimide (DCC), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).  
For DIC and DCC, it was thought that the urea side product would precipitate from the reaction 
solvent (DCM) and leave only product in solution.  For EDC, the urea product that forms is 
water-soluble and an aqueous wash in the work up should theoretically yield a cleaner product. 
However, in all cases 1H NMR revealed poor separation of the urea products and low coupling 
yields, possibly due to hydrogen bonding between the urea and PEG.  The final coupling reagent 
tested was carbodiimidazole (CDI) and its reaction by-products are CO2(g) and a water-soluble 
imidazole which, following aqueous separation, yielded a purer product than the use of all other 
coupling reagents (Figure 2.1.7). It should also be noted that it was observed that upon addition 
of only 1 equivalent of coupling reagent, the best yield obtained was 50%, which was likely due 
to the formation of a symmetric anhydride species in solution. This can be overcome by the 
addition of more coupling reagent 30 minutes to 1 hour after the initial addition of 1 equivalent 
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of coupling reagent which increases product yield to 65-81% after purification. A subsequent 




Figure 2.1.7.  1H NMR spectra comparison of crude Fmoc-Gln(mTEG)1-OPac 





Initial usage of the Mg/AcOH cleavage conditions39 allowed for the clean deprotection of 
OPac from the monoPEGylated glutamine derivative (Figure 2.1.8), however in the synthesis of 
later mPEG-amino acid derivatives, the removal of residual AcOH (or Mg(OAc)2) from the 
product was quite difficult.  
 
 
Magnesium is used in the literature39 instead of zinc because it would create less acidic 
salts upon phenacyl ester deprotection. Zinc is, in some respects, chemically similar to 
magnesium, because its ion is of similar size and its only common oxidation state is +2. The zinc 
would be oxidized, forming hydrogen gas and dissolving the zinc:  





































The presence of AcOH in solution with a desired Fmoc-amino acid during the solid phase 
peptide synthesis (SPPS) results in the coupling of AcOH to the growing peptide chain; 
effectively halting the peptide growth at that stage.  Therefore, in some cases, it was preferrable 
to use the Zn/acetylacetone(acac)/pyridine deprotection conditions43 (Scheme 2.1.4) to yield the 
desired products. Although the Zn deprotection is reported to work at 35 oC between 60-90 min, 
I routinely needed to elevate the temperature to 55-70 oC (Figure 2.1.9). Additionally, the 
solvent can be changed from DMF to ACN without hindering the product yield. This solvent 
change is favorable due to the difficulty in removing DMF from the final PEGylated amino 
acids. 
 




Alternative protecting groups and cleavage conditions are plausible. Instead of phenacyl 
ester a trichloroethyl ester protecting group would also be stable under similar conditions.  
Phenacyl ester however has been cleaved from amino acids in literature and has been reported to 
have no racemization of the alpha carbon,39 whereas the trichloroethyl ester has not. Allyl ester is 
most often used to protect carboxylic acids. Palladium is used in allyl ester removal, which is 
typically unrecoverable and on the large scale that I will be trying this method would not be cost 










The proposed synthetic route towards Fmoc-Gln(mTEG)2-OH was relatively 
straightforward once diPEG-amine was obtained (Scheme 2.1.5). Utilizing the previously 
synthesized Fmoc-Glu(OH)-OPac as a starting point, a diPEGylated amine needed to be 
synthesized and coupled to the free carboxylic acid. While some diPEGylated amines are 
commercially available, the typical price range can be as low as $700-1000 per gram, making the 
synthesis from cheaper starting materials an attractive first step. Subsequent deprotection of the 






































Scheme 2.1.5. Proposed synthetic route to Fmoc-Gln(mTEG)2-OH (2).  
 
There are various ways that diPEG-amine could be synthesized so it was a matter of 
determining which route was most efficient in practice and which would better fit our needs as 
far as undesired side products.  
It was decided that the first attempts would be to synthesize the diPEG amine by 
exploiting an E1cb mechanism, as seen in Scheme 2.1.6, because in theory this route should 
minimize the number of steps to the desired product and it should progress in high yield as long 
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as the appropriate leaving group is chosen correctly (i.e. styrene or isobutylene). Those leaving 










































Scheme 2.1.6. Attempted synthetic routes to (mTEG)2-NH. The two synthetic routes on the 
left assume an E1cb mechanism. Reagents and conditions: a) TEGME, Tf2O, DIEA, DCM, 0 
oC. b) TFA. c) SOCl2, DCM, 0 
oC. d) NaHMDS, Diethylene glycol monomethyl ether. 
 
TEGME was initially reacted with trifluoromethane sulfonic anhydride in DCM before 
the slow addition to a solution of DIEA and either t-butyl amine or 1-phenylethyl amine in 
DCM. The reaction progress was monitored by MALDI mass spectra; however, E1cb mechanism 
never seemed to go to completion; showing desired product as well as the diPEGylated 
intermediates.  
Alternatively, a synthetic route was attempted that aimed to PEGylate the alkyl groups of 
diethanol amine (Scheme 2.1.6). The conversion of the hydroxyls on diethanol amine into 
chlorides was accomplished with thionyl chloride, however the subsequent attempt at displacing 
the chloride with the sodium alkoxide salt of diethyleneglycol monomethyl ether (DEGME) was 
unsuccessful. NMR of the reaction products suggested unreacted DEGME. Even if the 
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aziridinium ion were to form, the desired product would have been obtained from nucleophilic 
attack and ring opening, suggesting the chloride may not have been present when alkoxide was 
added. If the reaction was in the presence of water from either the atmosphere, solvent or in one 
of the reagents, the chloride could have converted back into diethanol amine. Some possibilities 
for the presence of water are: 1) the atmospheric absorption of water over time by DEGME; and 
2) water condensation inside of the open reaction vessel due to the reaction being at low 
temperature. The reactions were not rigorously performed under water free conditions. 
At this point, alternative methods we sought and evaluated for their synthetic feasibility 
and efficiency. One literature route44 that was considered is shown below in Scheme 2.1.7. This 
route first involves trityl protecting diethanol amine by way of SN1 in a polar protic solvent. 
Next, the free hydroxyls are deprotonated and serve as nucleophiles in the displacement of 
tosylate from di(ethylene glycol) monomethyl ether (DEGME). A subsequent trityl deprotection 
under acidic conditions would yield the desired product in relatively good yields according to 
literature. This particular set of reactions was not very trustworthy due to the high possibility that 

























Scheme 2.1.7. Potential alternative route to mTEG2-amine.




Alternatively, a similar approach could be taken, where the free hydroxyl on DEGME 
can be converted into a leaving group and reacted with an N-boc-protected diethanol amine 
under basic conditions (Scheme 2.1.8A-B). A subsequent deprotection of the boc under acidic 
conditions (TFA/DCM or HCl/Dioxane) would yield the desired product and have more easily 
separable by-products, CO2 (g) and t-BuOH. A similar route can be envisioned where an N-
benzyl-protected diethanol amine is also reacted with an activated DEGME under basic 
conditions, followed by debenzylation under Pd-catalyzed hydrogenation (Scheme 2.1.8C). 
These proposed routes did not work successfully in liberating the desired mTEG2-amine due to 
failed attempts at synthesizing, isolating, and characterizing the N-boc or N-benzyl protected 
mTEG intermediates. In a separate project, we have also seen near-quantitative deprotection of 

















































































Scheme 2.1.8. A – synthetic route to diethylene glycol monomethyl ether (DEGME) 
derivatives with varying leaving groups. B – proposed synthetic route to (mTEG)2-amine via 
reaction between N-boc-diethanolamine and activated DEGME. C – proposed synthetic route 
to (mTEG)2-amine via reaction between N-benzyl-diethanolamine and activated DEGME.  
Reagents and conditions: a) tosyl chloride. b) SOCl2, DCM. c) NaI, acetone, reflux. d) Boc2O. 
e) NaH, ACN. f) TFA:DCM (3:1, v/v). g) benzyl bromide, K2CO3, MeOH, reflux. h) NaH, 
THF, 65 oC. i) H2, Pd/C, MeOH, 4h, r.t. j) Benzylamine, Na2CO3, ACN, reflux, 18 hr, 37-




The final route that was selected involved the synthesis of the benzyl protected diPEG 
amine through reacting benzyl amine with excess mesylated TEGME under reflux overnight. 
This reaction yielded the desired benzyl protected diPEG amine in decent yields. The subsequent 
benzyl deprotection was performed by Pd-catalyzed hydrogenation and was successful in 
converting all starting material into desired product as judged through MALDI analysis of the 































































































Figure 2.1.10. Mass spectrum analysis of product formation during the synthesis of di-mTEG 
amine.   
 
When coupling di-mTEG amine to Fmoc-Glu(OH)-OPac, the reaction worked best with 
propylphosphonic anhydride (T3P) as the coupling reagent, compared to using CDI, EDC, or 
DCC. Additionally, it’s important to note that when di-mTEG amine was stirred for 19 hrs in the 
 
 51 
presence of Fmoc-Glu(OH)-OPac, CDI, in a mix of dry ACN/DCM (1:1), MALDI analysis 
showed not only some desired product, but also the presence of Fmoc-deprotected product at m/z 
558.45. This is hypothetically due to the fact that the PEGylated amine being coupled is a 
secondary amine and Fmoc is usually deprotected with piperidine which is also a secondary 
amine with a pKa ~11. The imidazole that would be created during the reaction would have a 
pKa ~ 6.95 as seen in literature and, as such, should not be basic enough to deprotonate and 
deprotect Fmoc.  
 
Figure 2.1.11. 1H NMR solvent comparison of Fmoc-Gln(mTEG)2-OPac. Top trace is Fmoc-




One potential reason for the observed line broadening in chloroform (Figure 2.1.11) 
includes possible molecular aggregation. There could be intermolecular pi-stacking occurring in 
solution or maybe even a type of micelle formation with a hydrophilic tail (PEG chains) and 
hydrophobic head group (Fmoc and OPac protecting groups). This hypothesis could be tested 
with NMR diffusion experiments that are outside the scope of the current work. It is important to 
note that the OPac deprotected final product (subsequent synthetic step) shows sharp lines in 
































Scheme 2.1.9. Synthesis of Fmoc-Gln(mTEG)2-OH. Reagents and conditions: a) T3P, DIEA, 
MeCN, r.t., 18 h, 43%. b) Zn dust, acetylacetone, pyridine, EtOAc, 45 oC, 4 h, 40%. 
 
The deprotection of the phenacyl ester under Zn-catalyzed acidic reduction conditions 
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Figure 2.1.12. Retrosynthetic strategies for Fmoc-Gln(EDA-mTEG3)-OH (3) formation. 
 
The desired Fmoc-Gln(mTEG)3-OH product can theoretically be synthesized via two 
pathways arising from either C(O)-N (amide bond) or C-N bond disconnections as shown above 
(Figure 2.1.12). The first attempted route was to couple a N-Boc-ethylene diamine (N-Boc-
EDA) to N-Fmoc-Glu(OH)-OPac, followed by the PEGylation of the free amine through 
nucleophic additions. The second-generation strategy that was attempted involved 
prePEGylating the diamine linker and subsequently coupling that amine to glutamic acid. Both 





Scheme 2.1.10. Optimization of coupling strategy towards Fmoc-Gln(mTEG)3-OH. 
 
The coupling strategy of N-Boc-ethylenediamine to Fmoc-Glu(OH)-OPac needed to be 
optimized because the conditions used for coupling monoPEG-amine gave low yields (~20%) in 
this system. Therefore, a range of coupling reagents was tested to elucidate which would provide 
the cleanest crude product and best yields after purification (Scheme 2.1.10). 
Attempted coupling with PyBOP and carbodiimides such as CDI, DCC, DIC, and EDC, 
gave low yields of desired product (<12-38%). If there was any trace water present during the 
reaction, the PyBop reagent, which contains a dehydrating agent along with HOBt, should have 
yielded more product than the carbodiimides. However, T3P coupling to form the desired amide 




Figure 2.1.13. Representative 1H NMR showing the successful synthesis of the desired 
intermediate N-boc-protected structure.  
 
The attempted coupling of N-Boc-ethylenediamine to Fmoc-Glu(OH)-OPac with EDC-
HCl in the absence of base yielded a boc-deprotected desired product (Figure 2.1.14) in good 
yield upon purification. One of the side products isolated was the EDC-activated ester of Fmoc-
Glu(OH)-OPac by 1H NMR analysis, which is generally thought to be unstable. To potentially 
drive the reaction to completion and avoid any isolation of the activated ester, 6-Cl-HOBt was 
added to the coupling reaction and the activated ester was no longer observed as a side product 




Figure 2.1.14. Representative 1H NMR spectrum showing the successful synthesis of the 
desired intermediate (Fmoc-Gln(EDA)-OPac) from the use of EDC, which deprotected the N-
Boc-protecting group and eliminated the subsequent step.  
 
The initial reaction of Fmoc-Gln(EDA)-OPac with mTEG-OMs at room temperature in 





From these results, various changes were considered for increasing the yield of the 
desired triPEGylated product; 1) increasing the reaction temperature, 2) adding more base, and 
3) using an activated PEG with a better leaving group (i.e. triflate or iodide). Attempts are 








The reaction of Fmoc-Gln(EDA)-OPac with mTEG-OTf in the presence of DIEA at room 
temperature favorably produced the triPEGylated product. Alternatively, a reaction using mTEG-
OMs as the activated PEG yielded only diPEGylated product and when potassium iodide and 
heat were added to promote the reaction progress, the reaction products were neither desired 
products nor starting material. When the diPEG product was obtained from either route, it is 
important to note that small scale reaction attempts at converting Fmoc-Gln(EDA-mTEG2)-OPac 
into Fmoc-Gln(EDA-mTEG3)-OPac by subjecting this molecule to a further PEGylation using a 
triflate leaving group did show success via MALDI mass spectral analysis, however the 
conversion of Fmoc-Gln(EDA-mTEG2)-OPac to Fmoc-Gln(EDA-mTEG3)-OPac was not 
TEGME-OTf
 
Scheme 2.1.11. Summary of experimental observations during the PEGylation step of 




reattempted on a large scale with an objective of obtaining a percent yield due to the success of 
the mTEG-Oms route which was concurrently investigated.  
Upon deprotection of Fmoc-Gln(EDA-mTEG3)-OPac, there was no starting material 
observed in MALDI mass spectroscopic analysis at m/z 955. It is unclear what the [M-18]+ could 
be that is observed at m/z 818 (Figure 2.1.16). However, this sequence of reactions was 
attempted on both the asparagine (n = 0) and glutamine derivatives (n = 1), showing the same 
observation. Upon purification, the product and the [M-18]+ peak are observed to be two 
























70 oC, 5 hr
43% (2 steps, n=0)





















The mass difference of the products being 18 is very close to an OH loss, which a 
conversion from COOH to C(O)H could be imagined. However, 1H NMR analysis does not 
reveal an aldehyde proton. Further analysis of the 1H NMR shows that the Fmoc and PEG are 
attached to the molecule so the major side product is structurally similar to the desired product. 
Literature analysis suggests that under conditions that introduce trifluoromethane sulfonic 
anhydride (Tf2O) or zinc-catalysis, a chemoselective reduction of an amide to an imine or amine 
is plausible (Figure 2.1.17). Additionally, it has been observed in literature that the presence of 
electron withdrawing groups near the amide increases the speed of reactivity. 
 
Figure 2.1.17. Proposed effect of any unreacted Tf2O on Fmoc-Gln(EDA)-OPac. 
a Synlett. 






We propose that under our PEGylation conditions, the secondary amide is being reduced 
to the secondary aldimine and not further reduced to the secondary amine. Since there is only a 
slight excess of Tf2O in these reaction conditions yet the side product predominates over the 
desired product, perhaps triflic acid (CF3SO3H) also promotes the amide reduction. Under acidic 
conditions, the amide is preferentially protonated at the carbonyl oxygen (Figure 2.1.18).45, 46, 47, 
48 It is believed that the reductive conditions, Mg/AcOH or Zn/pyridine/acetylacetone, are not an 
efficient system for the reduction of an imine to an amine. The proposed OTf-intermediate is 
very similar to the POCl3-activated amide intermediate from a Vilsmeier reaction. Imines are 
typically stable under anhydrous conditions, but unstable to hydrolysis under aqueous conditions; 
especially under acid catalysis. It is believed that the aliphatic alkyl substituients on both the 
imine nitrogen and carbon atoms adds to the stability of the imine. Due to this undesired 
reduction, the focus shifted to the other strategy illustrated in Figure 2.1.12. 
 
 






2nd Generation Strategy. In a one pot-like reaction, the free amine of N-Boc-ethylene 
diamine can be alkylated to a quaternary ammonium in the presence of mTEG-OTf as long as 
there is an excess of base present (6 equiv.). Multiple attempts suggest that even in the presence 
of the smallest amount of triflic acid (TfOH), a side product of the reaction, can deprotect the N-
Boc and lead to the undesired alkylation of both amines. Additionally, the base selection and 
solvent are important. K2CO3(s) worked well in a 1:4 mixture of MeCN:DCM, however 
Na2CO3(s) and TEA were unsuccessful at formation of the triPEGylated intermediate. Upon 
confirmation of N-Boc-protected triPEGylated product from mass spectral analysis, the reaction 
mixture is partitioned between ice water and DCM, before collecting the organic layer and 
concentrating it down. A TFA:DCM (3/1, v/v) deprotection of N-Boc for 1 h to liberate the free 
amine, evaporation of solvent, followed by the amide bond formation between the crude 
triPEGylated amine and Fmoc-Glu(OH)-OPac, employing T3P as the coupling agent, yielded the 
desired N-Fmoc and –OPac protected triPEGylated product (Scheme 2.1.12) by NMR and 
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Scheme 2.1.12. Attempted 2nd generation strategy leading to Fmoc-Gln(mTEG)3-OH. 
Reagents and conditions: a) K2CO3. b) TFA:DCM (3:1, v/v). c) T3P, ACN, 2h, r.t. d) Mg, 
MeOH:DMF (8:2, v/v), AcOH, 1h. 
 
The subsequent phenacylester deprotection with Mg/AcOH of the Fmoc-Gln(mTEG)3-
OPac material did not yield product nor starting material by MALDI ([M-51]+, [M-51+Na]+, [M-








SCALABLE SYNTHESIS OF FMOC-PROTECTED LINEAR AND BRANCHED 





































Figure 2.2.1. Current peptide PEGylation strategy using amine conjugation chemistries. R = 
PEG chain. Black circles = amino acids chemically linked through amide bonds into a 
peptide. 
 
The PEGylation of lysine is one of the most extensively used strategies for peptide 
incorporation due to the accessibility of lysines on the solvent-exposed surface. The current 
PEGylation strategy for researchers typicaly falls into one of few categories (Figure 2.2.1): 1) 
reductive amination of a free amine with a PEG-aldehyde. This route allows for improved 
selectivity over the usage of PEG-NHS esters, but is typically performed on the N-terminus due 
to the pKa difference between the N and N amine, 6.8-8 and 10.8, respectively; 2) amide bond 
formation using a PEG-NHS ester. This pathway, typically used on lysine’s side-chain amine 
within peptide sequences, loses the typical charged nature of lysine residues in solution; 3) 
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oxime formation specifically on the N-terminus. To date, there are no examples of PEGylated 
lysine monomers available for direct usage in SPPS.  
It is known that the strategy of PEG conjugation to a peptide has a strong impact on the 
conformational stability.49 Amide bond coupling can lose the charged nature of the amine when 
under biological conditions meaning the lysine side chain is less likely to participate in any 
favorable salt-bridges or pi-cation interactions with other residues (Figure 2.2.2). Thus, the 
design and synthesis of PEG-lysine conjugates that do not convert the side-chain amine into an 
amide would be highly relevant and useful tools for the study of peptide PEGylation benefits.  
 
Figure 2.2.2. Typical peptide stabilizing interactions that occur with lysine in its cationic 
form. 
 
It has already been mentioned that one reason for the selection of lysine was due to its 
presence as one of the more solvent accessible amino acid residues present in peptides and 
proteins because of its role in aiding solubility. Therefore, we propose various PEGylated 
analogues of lysine (Figure 2.2.3) and have synthesized them to demonstrate the feasibility of 




























































Figure 2.2.3.  Synthetic mTEG lysine targets of interest. 1 – N-Fmoc-mTEG1 lysine.  2 – 
N-Fmoc-mTEG2 lysine. 3 – N-Fmoc-mTEG3 lysine. 4 – N-Fmoc-mTEG1 lysine (N-
biotin). 5 – N-Fmoc-mTEG1 lysine (N-fluorescein). 
 
RESULTS AND DISCUSSION 
 
Synthesis of Fmoc-Lys(mTEG1)-OH Derivatives & Fmoc-Lys(mTEG2)-OH 
 





The selected route towards monoPEGylating lysine is shown mechanistically by Figure 
2.2.4 and involves performing a reductive amination between N-Fmoc-Lys(NH2)-OPac and a 
mTEG-aldehyde. Being that mTEG-aldehyde has been synthesized in literature,50 this provided 
us with a 1H NMR to compare our product to (Figure 2.2.5).  
 
Figure 2.2.5. Aldehyde NMR comparison with literature50 to demonstrate that aldehyde can be 
used without further purification for reductive amination.1996 spectrum was reported after 
column purification.  
 
After successful synthesis of mTEG-aldehyde, the crude material was reacted with the 
free side-chain amine on N-Fmoc-Lys(NH2)-OPac prior to reducing the intermediate imine with 
NaCNBH3. The initial 
1H NMR of the crude product suggested successful synthesis of desired 
product (Scheme 2.2.1). However, upon purification, NMR analysis suggested phenacyl ester 
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deprotection. If the carboxylic acid is deprotected at this stage in the proposed reaction sequence, 
the subsequent reactivity of the secondary amine with a biotin or fluorescein carboxylic acid in 









































Scheme 2.2.1. 1H NMR of crude product from reductive alkylation conditions on Fmoc-
Lys(NH2)-OPac suggests monoPEG product (Fmoc-Lys(mTEG)1-OPac).  
 
It was determined that a protecting group was not necessary to obtain the desired final 
product, Fmoc-Lys(mTEG)1-OH, from the reductive amination to attach PEG. Reactions were 
performed where the starting material no longer contained a phenacyl ester group during the 
reductive amination protocol because the carboxylic acid would not be reduced under such 
conditions. Resulting spectra from isolated purification fractions suggested diPEGylation of the 
lysine side chain (Scheme 2.2.2), which was surprising when thinking about the mechanism of 
reactivity. This result, however, was duplicated in multiple experiments and observed in 
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fractions after multiple column purifications, producing the possibility that excess PEG was 
streaking along the silica column and eluting with desired product. It was also found that Fmoc-
Lys(mTEG)2-OH is water soluble while Fmoc-Lys(mTEG)1-OH is not. This difference in 






































































Scheme 2.2.2. 1H NMR of purified Fmoc-Lys(mTEG)2-OH from reductive alkylation of Fmoc-
Lys(NH2)-OH.  
 
This type of diPEGylation, while not commonly observed in literature, has nonetheless 
been reported by researchers at Johnson and Johnson with certain types of aldehydes, such as 
straight chain aldehydes, and with primary amines from - and -amino esters.17,18,47,20 The 
researchers found their desired monoalkylated product in the presence of 15-20% dialkylated 
product and proposed a plausible mechanism as seen below in Figure 2.2.6. They believed that 
the reduction of the imine was occurring slowly in solution, leaving the secondary amine to react 
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with the imine. They then proceeded to perform a reaction with an imine and a secondary amine 
under reducing conditions to show that the dialkylated product is indeed formed. 
 
Figure 2.2.6. Top – proposed mechanism for dialkylated product formation. Bottom – 
reaction performed by the same researchers to confirm that an imine reacting with an amine 
in the presence of reducing conditions will form dialkylated amine. Synlett 1994, 1, 81-83. 
 
I hypothesize that the initial formation of the dialkylated product differs from the 
proposed mechanism found in literature due to reproducible mass spectral evidence that shows 
the formation of dialkylated product prior to the addition of borohydride. Under my experimental 
conditions, it is not a matter of how fast the imine is reduced because the dialkylated product is 
forming under slightly acidic conditions. However, it is plausible that the subsequent addition of 
a borohydride reagent, such as NaBH4 or NaCNBH3, could potentially lead to the formation of 





Figure 2.2.7. Proposed acid-catalyzed mechanisms of mTEG2-Lys formation.  
 
The use of NaCNBH3 is favorable under biological conditions because it is stable to 
aqueous and slightly acidic conditions. These reasons make the formation of an imine crosslink 
plausible in the presence of NaCNBH3 with a slow reduction of imine. Biologically, similar 
imine crosslinking reactions occur as imine intermediates from the oxidation of lysine side 
chains by lysyl oxidase react with N-amines from lysine.  
Two different crosslinking mechanisms could be occurring in solution. The imine 
crosslinking mechanism (Figure 2.2.7), which is similar to the literature proposed mechanism, 
begins with the protonation of the imine nitrogen to the iminium salt, making the imine carbon 
position more electrophilic. After a nucleophilic attack by an N-amine and a proton transfer, 
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there is an expulsion of a primary amine upon imine formation. The nucleophilic addition of the 
hydride leads to the reduced diPEGylated amine.  
It is not surprising that aldol-like reactivity is observed from the reductive amination of 
the aliphatic amine with a linear aldehyde. The aldol-like crosslinking mechanism proceeds 
under acid-catalyzed conditions and in the absence of any reduced amine to react with the imine. 
Initially the imine tautomerizes into an enamine which can proceed to do an intermolecular 
nucleophilic attack on the imine carbon (C=N). The subsequent loss of an amine is driven by the 
formation of a conjugated pi-system.  
As results suggest, there is a mass corresponding to diPEGylated lysine prior to the 
addition of borohydride reagent making it plausible to think the aldol-like crosslink is the 
predominant linkage. However, if NaCNBH3 is then added and it is observed that additional 
diPEG lysine is formed, then it is also hypothetically plausible to think that there may be a 
mixture of the two products which may be very difficult to separate via column chromatography. 
Analysis of the TLC does show two very close spots, which could be supporting evidence for a 
mixture of both diPEGylated products. Since the aldol-like crosslink leads to a secondary amine 
which could form an amide, whereas the imine crosslink would form a tertiary amine incapable 
of forming an amide, a reactivity test could help confirm the prescence of both analogs. NMR 
proof of the aldol-like cross-link would be difficult to obtain even from a pure sample due to the 
overlap of all the PEG proton signals. A test reaction of purified diPEG lysine product, from 
reductive alkylation, in the presence of excess HCTU and 6-Cl-HOBt resulted in a mixture of 
cylized product and unreacted starting material by mass analysis. This result supports the 
presence of both structural isomers of diPEG lysine being formed.  
 
 73 
Upon searching the literature, a new potential route was selected in an attempt to 
minimize any diPEGylated product and maximize the monoPEG. This route involves a radical 
reaction and was shown to work in various cases.48 However, when attempted multiple times, 
there was only minimal conversion (< 5 %) of N-Fmoc-Lys(NH2)-OAll into desired 
monoPEGylated product. This was further confirmed by subsequent reactivity with activated 
fluorescein and detection of minimal Nε-mTEG-Nε-fluorescein-labeled product by MALDI-MS.  
Literature Precedent:
Application of Lit. Procedure to Our System:



















R = H orR
<10%
 
Scheme 2.2.3. Top - literature precedent for a radical reaction to form imine from a benzylic 
alcohol and benzylic amine. Bottom – proposed reaction using literature conditions to form 
monoPEGylated lysine. 
 
Literature from other researchers gives possible explaination to our poor yielding 
attempts at converting tri(ethylene)glycol monomethyl ether into tri(ethylene)glycal monomethyl 
ether.49 There are some potential limitations of using the proposed radical reaction route within 
our proposed chemical system: (1) it has been noted by authors that in some cases, alcohols 
containing a vicinal heteroatom, such as an ether, underwent slow or incomplete oxidation,49 (2) 
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if COOH is present and unprotected during the reaction, uncontrolled reactivity can, not 
surprisingly, occur with this functional group. Additonally, the presence of the acidic O-H has 
been theorized to potentially prevent the formation of a reactive Cu-alkoxide species.49   
The other potential route to PEGylating lysine is via nucleophilic addition. However, as 
expected, the reactivity was difficult to control unless triPEG was the desired product; creating 
mixtures of either starting amine and mono-PEG or mono- and diPEG, depending on the reaction 
conditions and the amount of activated mTEG and/or base added. The product mixture from this 
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Figure 2.2.8. Synthetic route to mixture of mono-, di-, and triPEG lysine via nucleophilic 
addition. MALDI analysis of increasing equivalents of activated PEG to Fmoc-Lys(NH2)-OPac.  
 
While mono- or diPEG products cannot be produced exclusively in a controlled fashion 
via this route, the mixture obtained can be controlled (Figure 2.2.8). The separation of products 
(Fmoc-Lys(mTEG)1-OPac and Fmoc-Lys(mTEG)2-OPac) via silica chromatography is tedious 
but allows for the isolation of mono- or diPEG products in good yield (~50%) (Scheme 2.2.1). 
However, if Fmoc-Lys(mTEG)2-OPac is the desired product, then performing the alkylation 
reaction very carefully to get a mixture of the desired product with Fmoc-Lys(mTEG)3-OPac 
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would be optimal because it is easier to separate compared to a mixture of mono- and diPEG. 
The separation of di- and triPEGylated lysine is optimal when the -COOH is protected as the 
phenacyl ester (Figure 2.2.9); upon deprotection, the di- and triPEGylated lysine products 
overlap using RP-HPLC.  
 
Figure 2.2.9. Analytical HPLC of crude product mixture containing Fmoc-Lys(mTEG)2-
OPac and Fmoc-Lys(mTEG)3-OPac. 
 
The Zn-catalyzed removal of OPac from diPEGylated lysine results in the isolation of the 
































































Scheme 2.2.4. Synthesis of Fmoc-Lys(mTEG)1-OPac and Fmoc-Lys(mTEG)2-OPac via 










































R  = Boc, Biotin,
         or Fluorescein
23%-Quant.
 
Scheme 2.2.5. Proposed route to N-Fmoc-N-(Biotin/Boc/Fluoresein)-mTEG1-Lys-OH 
analogues. 
 
Orthogonally protected lysines are often used to functionalize the side chain with a 
fluorescent moiety or biotin which are highly hydrophobic. Therefore, a lysine pre-
functionalized with one of those moieties and a PEG for solubility would be doubly 
advantageous. The most straight-forward way of difunctionalizing the N-amine of lysine with 
PEG and either boc, biotin, or fluorescein would be through the reductive alkylation of the free 
amine (Scheme 2.2.5) with the appropriate mPEG-aldehyde and a subsequent amide bond 
formation. While mono PEGylation of N-Fmoc-lysine can be accomplished with a protecting 
group on the -COOH through nucleophilic addition, the product yield often suffers as a result 
of multiple alkylation. While the reductive alkylation route has also shown to produce a mixture 
of mono- and diPEGylated species, various conditions were attempted to tune the product 




The conditions tested for their ability to preferentially form mono- versus diPEGylated 
lysine were: 1) order of reagent addition; 2) reducing agent; 3) solvent selected; 4) length of time 
for reaction; and 5) the presence of the -phenacyl ester. When the phenacyl ester was present as 
the protecting group for the -COOH, it consistently deprotected under the reaction conditions. 
However, surprisingly, the presence of the phenacyl ester led to the formation of more 
monoPEGyated lysine product. It’s noteworthy to mention that when MeOH was used as the 
reaction solvent, there was often formation of a significant amount of methyl ester which 
lowered the amount of desired product recovered. While it was seen that the amount of 
PEGylation could be controlled under reaction conditions, there was no observable benefit over 
the nucleophilic addition of PEG to Fmoc-Lys(NH2)-OPac. 
Table 2.2.1. Optimization of reductive amination conditions to favor formation of mono- 









(i) mix aldehyde and amine, stir 3 hrs, add reducing agent. Stir o.n.
(ii) mix aldehyde, amine, and reducing agent. Stir o.n.
(iii) mix aldehyde and amine, stir 3 hrs, add reducing agent and stir for 10 mins. 

































































































Scheme 2.2.6. Top - Synthetic route to Fmoc-Lys(mTEG)1-OAll through a TEMPO-
activated radical reaction. Bottom – Synthetic route to N-Fmoc-N-Fluorescein-
Lys(mTEG)1-OAll. 
 
The initial attempts at synthesizing Fmoc-Lys(mTEG)1-OAll through a TEMPO-
activated radical reaction (Scheme 2.2.6) generated poor product yield after purification (as 
mentioned earlier) even though there were a few spots observed in the TLC analysis and the 
separation was not difficult via silica chromatography.  
A small-scale (45 mg) test coupling reaction was attempted with the purified Fmoc-
Lys(mTEG)1-OAll product from the radical TEMPO-activated PEGylation procedure. MALDI 
analysis revealed that the desired product was formed in the reaction mixture and the 1H NMR 
analysis also suggested the desired product (with impurities) upon comparison with the predicted 
spectrum. No starting material (Fmoc-Lys(mTEG)1-OAll) was observed in the MALDI analysis 
of the product, indicating that it had all been consumed during the reaction.  
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Further attempts to synthesize N-Fmoc-N-Fluorescein-Lys(mTEG)1-OAll through this 
route gave similar results, however MALDI analysis indicated that not only was there some 
desired product present, but there was also N-Fmoc-N-Fluorescein-Lys-OAll. So the fact that 
the PEG chain was absent in some of the product, confirms that the radical reaction was not a 
successful strategy to employ for this molecular system as discussed earlier. 
 
 
Scheme 2.2.7. Synthetic route to NHS-activated biotin and fluorescein. 
 
An alternative functionalization strategy was then sought that activated the biotin and 
fluorescein carboxylic acids into N-hydroxy succinimide (NHS)-esters (Scheme 2.2.7). The 
initial attempt at synthesizing this NHS-activated biotin with EDC, instead of DCC, at room 
temperature (22-25 oC) for 18 h, produced very poor results with a mixture of desired product 
and unreacted starting material present by MALDI analysis. After isolation of desired fractions 
from purification, NMR analysis did not support product formation because the spectra did not 
match spectra reported in literature.  
Literature precedent for NHS-activated fluorescein and biotin conjugates were followed 



































































Scheme 2.2.8. Attempted route to N-Fmoc-N-Biotin-mTEG1-Lys-OH and N-Fmoc-N-
Fluorescein-mTEG1-Lys-OH via reductive alkylation product. 
 
Amide bond formation was attempted between the N-amine of Fmoc-Lys(mTEG)1-OH 
from reductive alkylation and the NHS-esters of biotin and fluorescein (Scheme 2.2.8). Upon 
purification of the reaction, the starting materials were obtained unreacted with only trace 
amounts of desired products present by MALDI analysis. One hypothesis for the limited 
reactivity is that the reaction needed more time to react because NHS esters react significantly 
slower with secondary amines than they do for primary amines. Another hypothesis for the 
limited reactivity could be that the NHS-esters could have limited solubility in the DMF. This is 
plausible especially in the case of biotin-NHS because upon isolation from silica 
chromatography, it was only soluble in d6-DMSO as opposed to d4-MeOD, CDCl3, D2O, nor d6-
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acetone. To test this hypothesis, DMSO was used as a reaction solvent and the reaction was 
carried out in the presence of Cs2CO3.  
 
Figure 2.2.10. Alternative strategies for the synthesis of bifunctionalized N-lysine 
conjugates. 
 
Alternative hypotheses for the limited reaction of NHS-esters with Fmoc-Lys(mTEG)1-
OH are that: 1) some minor side products from the reductive alkylation process carried through 
the purification and are interfering with reactivity; 2) Having a vicinal oxygen atom neighboring 
the N-amine is decreasing the nucleophilicity of the nitrogen lone pair; or 3) The -carboxylic 




To test these hypotheses, OPac-protected monoPEGylated lysine was synthesized from a 
nucleophilic alkylation reaction and reacted with biotin-NHS and fluorescein-NHS in DMSO 
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Scheme 2.2.9. Attempted route to N-Fmoc-N-Biotin-mTEG1-Lys-OH (top) and N-Fmoc-N-
Fluorescein-mTEG1-Lys-OH (bottom) via nucleophilic alkylation product.  
 
The reaction of Fmoc-Lys(mTEG)-OPac with Fluorescein-NHS in the presence of base 
(either DIEA or Cs2CO3) (Scheme 2.2.9) repeatedly yielded a product with a m/z ratio of 959, 
however the desired product has a molecular weight of 947 g/mol. It is unclear as to what could 
yield the [M+12]+ peak that is observable in MALDI-MS. Analysis of the purified material by 1H 
NMR suggested that the fluorescein was attached to the fmoc and phenacyl ester protected 
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lysine. Upon phenacyl ester deprotection with Mg/AcOH, the desired N-Fmoc-N-Fluorescein-






A test reaction on the N-Boc-protected material showed that the boc was not stable to the 
mild acidic reduction conditions, yielding complete OPac and N-Boc deprotection after 4 h at 































Scheme 2.2.10. Attempted synthetic route to N-Boc-N-Fmoc-Lys(mTEG)1-OH. 
 
Therefore, the phenacyl ester needs to be deprotected prior to N-Boc-protection. The 
attempted N-Boc-protection of monoPEG lysine material from reductive alkylation conditions 
resulted in low isolated yield (Scheme 2.2.11 – Top). To rule out the usage of hydrolyzed boc 
anhydride (Boc2O), NMR analysis supported that the reagent was not decomposed to tert-
butanol. Alternatively, the Fmoc-Lys(mTEG)1-OPac obtained from nucleophilic addition was 
deprotected and subsequently reacted with boc anhydride to produce the desired N-Boc-N-
Fmoc-Lys(mTEG)1-OH (Scheme 2.2.11 – Bottom). This sequence of reactions resulted in 
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phenacyl ester deprotected material after stirring with Mg/AcOH, but after a workup and 
subsequent reaction with boc anhydride in THF/tBuOH there was no bocylated product was 










































Scheme 2.2.11. Synthetic routes to N-Boc-N-Fmoc-Lys(mTEG)1-OH. 
 
Potential Future Synthetic Route. Very recently, it has been observed that proline and 
piperidine derivatives can be selectively oxidized to the 5- and 6-hydroxy compounds, 
respectively, using iron catalysis (Figure 2.2.12A and C). This versatile hydroxy intermediate 
can subsequently be reacted with an amine and reducing agent to open up the ring and form a 
methoxyethyl amine linkage while retaining the correct stereochemistry (Figure 2.2.12B). A 
possible future route towards Fmoc-Lys(mTEG)1-OH, could be envisioned (Figure 2.2.12D) by 
beginning with the appropriate piperidine analog and oxidizing to the hydroxy compound prior 
to reaction with a mPEG-amine of desired length and reducing agent such as NaCNBH3. This 
route would first require the synthesis and isolation of the iron catalyst. According to literature, 
the Fmoc protecting group is stable to peroxyacid, and from experimentation, it is known that it 
is stable to metal (Mg and Zn)/AcOH conditions. However, the Fmoc stability under these 





Scheme 2.2.12. A – Literature examples of selective oxidation of proline to 5-hydroxyproline 
(top) and piperidine to 6-hydroxypiperidine (bottom) using iron catalyst.50  B – Literature 
example of proline oxidation to open-chain monomethoxy ornithine derivative. C – Iron 










The lysine side-chain is typically protonated under physiological conditions and 
participates in salt bridges (Figure 2.2.11). A salt bridge is actually a combination of two 
noncovalent interactions: hydrogen bonding and electrostatic interactions. This is most 
commonly observed to contribute stability (~3-4 kcal/mol up to 8 kcal/mol if buried in a protein 
interior) to the folded conformation of proteins. Although noncovalent interactions are known to 
be relatively weak interactions, small stabilizing interactions can add up to make an important 
contribution to the overall stability of a conformer. 
 
Figure 2.2.11. Salt bridge interactions between glutamic acid and lysine under 
physiological conditions. 
Originally, the plan was to synthesize diPEG-lysine via the nucleophilic addition route. 
However, what we not surprisingly observed through experimentation is that we were 
consistently not only making diPEG, but also tri-PEG in solution due to the great leaving group 
ability of the triflate. As mentioned earlier, the two products are separable from each other by 
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column chromatography because the N-Fmoc-Lys(mTEG)3-OPac (Rf ~ 0.18 in 5% MeOH in 
DCM), N-Fmoc-Lys(mTEG)2-OPac (Rf ~ 0.58 in 5% MeOH in DCM). Additionally, if any N-
Fmoc-Lys(mTEG)1-OPac is present, it can also be isolated from the reaction; having an Rf ~ 
0.39 in 5% MeOH in DCM. When Fmoc-Lys(NH2)-OPac is used in the presence of TfO-mTEG 
and excess DIEA, the major product is Fmoc-Lys(mTEG)3-OPac (Figure 2.2.12) with no 








































Figure 2.2.12. 1H NMR and MALDI-MS spectrum showing Fmoc-Lys(mTEG)3-OPac. 
 
The mild Mg-catalyzed acidic deprotection of phenacyl ester to liberate the carboxylic 
acid that is present in the final product went to completion as monitored by mass spectrum 
analysis (Scheme 2.2.13). However, there was a tedious purification that was necessary to obtain 
pure Fmoc-Lys(mTEG)3-OH. The desired product was very polar and purification via normal 
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silica gel is not the optimal method to be used. Alternatively, it would likely be better to do 
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Scheme 2.2.13. Synthetic route to Fmoc-Lys(mTEG)3-OH using OPac ester and MALDI-MS 
spectrum showing the presence of Fmoc-Lys(mTEG)3-OH. Reagents and conditions: a) 
Bromoacetophenone, Na2CO3, N(Bu)4Br, DCM, r.t., 24-72 h, 95-98%. b) 3:1 (v/v) TFA:H2O, 
r.t., 2 h, quant. c) Triethylene glycol monomethylether (mTEG), (Tf)2O, 0 
oC, 1 h, 73%. d) Mg, 
AcOH, MeOH, DMF, r.t., 63%-quant. 
 
An alternative protecting group was selected for attempting to synthesize the 
triPEGylated lysine derivative due to the original difficulty in trying to remove all of the AcOH 
from the desired product. Any residual AcOH is a problem for SPPS conditions because AcOH 
will couple to a peptide sequence instead of the desired PEGylated lysine. The phenacyl ester 
deprotection conditions of Fmoc-Lys(mTEG)3-OPac using Zn catalysis worked at higher 
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temperatures (~70-75 oC), but the isolated yield was slightly lower than deprotection with 
Mg/AcOH. Allyl ester deprotection can be done under Pd-mediated conditions in the absence of 





































dry THF, r.t., 24 hr
49% (over 2 steps)
[M]+ =	847.5
 
Scheme 2.2.14. Synthetic route to Fmoc-Lys(mTEG)3-OH using O-Allyl ester and a 
representative MALDI-MS showing the presence of desired Fmoc-Lys(mTEG)3-OAll.  
 
The reaction of Fmoc-Lys(NH2)-OAll with mTEG-OTf (3 equiv.) in the presence of 
excess DIEA allows for the formation of the desired triPEG-product (Scheme 2.2.14). The Pd-
catalyzed deprotection of the allyl ester leads to the desired final product in good yield (49%) 
over two steps, but there was no significant advantage of this method over deprotecting the OPac 





Site-Specific Peptide Incorporation of Linear and Branched Amino Acid Monomers 
Upon sysnthesis of desired Fmoc-protected amino acid building blocks, they were 
incorporated into traditional Fmoc solid-phase peptide synthesis (SPPS) (Scheme 2.3.1) to 
demonstrate that they could be selectively placed anywhere within a peptide sequence.  
The resin used was dependent on the type of C-terminus needed in the desired peptide 
sequence of interest. Wang or 2-chlorotrityl is used for incorporation of a carboxylic acid at the 
C-terminus. Rink amide was utilized to incorporate an amide at the C-terminus.  On wang resin, 
coupling of the first residue takes the longest due to the need for a symmetric anhydride to 
couple the first residue to the resin. The cleavage conditions for trityl resins are mild enough that 
the side chain protecting groups can be retained. These various factors were taken into 
consideration when selecting the proper resin for each peptide sequcnce.  
The coupling reagents used were HCTU and 6-Cl-HOBt. The cleavage conditions used 
were 95% TFA, 2.5% H2O, and 2.5% Triisopropylsilane. Some other cleavage conditions that 
are used by researchers for Wang and rink amide resins are (1) 95% TFA, 2.5% H2O, 2.5% 









Peptide Synthesis. Regulation of appetite is critically important, both in its suppression 
for the treatment and prevention of obesity and diabetes, as well as for inducing hunger in 
patients suffering from severe morbidities, such as heart failure, chronic obstructive pulmonary 
disease, and chemotherapy-induced cachexia.  Almost all of the relevant signaling hormones are 
peptides with molecular weights that hinder mimicry or blocking of their actions with small 
molecule drugs.   
 
Table 2.3.1. Sequences of the peptides of interest. Amino acids in bold represent 
potential modification sites of interest. 
Sample Sequence 
Human GLP-1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 
Exenatide HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
Liraglutide HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG-NH2 
Lypressin CYFQNCPKG-NH2 (Disulfide bridge: C1-C6) 
Sup35 NDFQKQQKQA (127-136) 
 
 
Glucagon-like-peptide 1 (GLP-1) is one of the most important peptide hormones 
controlling appetite (Table 2.3.1).  GLP-1 is the primary hormone responsible for appetite 
suppression and also beneficially increases glucose-dependent insulin production and restores 
insulin sensitivity.51, 52  Since GLP-1 restores important natural functionality that is lost in 
diabetes patients, longer-lasting versions of GLP-1 are desirable.  Unsurprisingly, five important 
diabetes drugs (exenatide, liraglutide, lixisenatide, albiglutide, and dulaglutide) are GLP-1 
analogs.  GLP-1 is degraded by the ubiquitous catabolic enzyme dipeptidyl peptidase IV (DPP4) 
that cleaves off an essential N-terminal dipeptide moiety.53, 54 This cleavage is the major route of 
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elimination of GLP-1 in the body leading to its short half-life (1.5-2.1 mins),55 and several 
effective treatments for diabetes are small molecule DPP4 inhibitors (saxagliptin, sitagliptin, 
vildagliptin, and linagliptin). Although natural GLP-1 has highly beneficial anti-diabetic effects, 
native GLP-1 is so short lived so as to be therapeutically useless (hypothetically requiring 
continuous infusion to exert the beneficial effect). Proteolytic degradation is also a problem for 
the GLP-1 analog drugs, such as exenatide and liraglutide, thus demonstrating the need for 
effective PEGylation strategies for GLP-1 (analogs).   
Given the crystal structure (PDB ID: 3IOL) of GLP-1 bound to the extracellular domain 
of GLP-1 receptor (Figure 2.3.1), it is theoretically possible to predict which modification sites 
won’t disrupt the receptor binding of the PEG-modified peptides. Additionally, potential site 
selection benefits take into account the studies in literature that have evaluated the beneficial 
effects of PEGylating GLP-1 at positions Lys26, Lys34 and Gln23 with chain lengths varying from 





Figure 2.3.1. GLP-1 bound to extracellular domain of GLP-1 receptor. (GLP1R) PDB ID: 
3IOL. H - His - Ala - Glu - Gly - Thr - Phe - Thr - Ser - Asp - Val - Ser - Ser - Tyr - Leu - 
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Figure 2.3.2. MALDI-mass spectra of unpurified PEGylated GLP-1 pentamer and unmodified 




The preliminary results presented above (Figure 2.3.2) show that Fmoc-Lys(mTEG)3-
OH can be incorporated into GLP-1 (7-36 amide) even though the full-length sequence has not 
been synthesized. 
There was initially an issue in the case of coupling the (mTEG)1-Gln to a growing 
peptide chain, which could have been the water molecules that are intimately associated with the 
PEG chain.  The 1H NMR of the (mTEG)1-Gln showed at least 3-4 equivalents of water per 
amino acid, which could disrupt the amide bond formation in coupling.  To remedy this issue, I 
attempted to use an EDC/HOBt mixture when coupling the PEG amino acid as well as the 
subsequent amino acid.  EDC was used because of its dehydrating nature as opposed to 
originally using HCTU, but this method was unsuccessful. 
The next attempt was to increase the reaction time for the coupling of the PEGylated 
glutamine.  The 1H NMR shows the presence of the polar solvent DMF with the product due to 
the deprotection conditions used.  While polar solvents solvate polar reagents and make SN2 
reactions proceed slower, it is better to have a slow reaction than no reaction at all.  After two 5-
minute couplings of (mTEG)1-Gln, a very small peak at the desired m/z ratio was observed 
amongst other products.  
Subsequent attempts at incorporating (mTEG)1-Gln into the synthesis of PEGylated GLP-
1 analogues yielded site-specifically modified analogues at positions Q9 and Q23 as shown 
below (Figure 2.3.3).  These following attempts utilized reacting 4 equivalents of PEGylated 
amino acid with the resin in the presence of HCTU for 10 minutes, twice. The next amino acid 






Figure 2.3.3. Analytical HPLC and MALDI-MS spectra for the confirmation of identity and 




After GLP-1 analogues were synthesized, lypressin analogues were attempted with the 
PEGylated amino acid monomers previously discussed in earlier sections of this dissertation.  
Lypressin is an analogue of Vasopressin, which is a first line treatment option for a complication 
of liver disease known as gastroesophageal bleeding as well as for septic shock. To our 
knowledge, short chain PEGylation has not been reported for either sequence (GLP-1 nor 
Lypressin). Our PEGylation attempts were successful in producing the desired lypressin products 
(Figures 2.3.4 and 2.3.5). The production of (mTEG)1-Gln
4-Lypressin, shows another product 
that is 191 mass units lower than the desired product at 1011.552. This observed lower mass is 
too low to reflect a missing PEG-glutamine and the closest attempts at matching the weight 
resulted in a potentially missing proline and cysteine; however, a missing proline and cysteine 







Figure 2.3.4. Site-specific peptide PEGylation examples with mass spectrum analysis 






Figure 2.3.5. Site-specific incorporation of Fmoc-Lys(mTEG)3-OH into varying positions within 
a lypressin peptide sequence. 
 
Conclusion 
In summary, we have developed an efficient and straightforward synthesis of peptides 
containing short PEG chains via PEG amino acid building block incorporation into standard 
Fmoc SPPS. The general availability of these building blocks gives access to any desired 
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PROGRESS TOWARDS THE IMPROVED SYNTHESIS OF FREIDINGER-LIKE LACTAMS 

















Figure  3.1. A) Structure of a prototypical Freidinger lactam. B) Generic Freidinger-like lactam 
framework that is particularly useful given the number of literature references. 
Freidinger lactams are an important molecular framework in pharmaceutical 
development. On the top left is a general structure of a Freidinger lactam. On the right is a 
generalized substructure that has greater than 2000 patent references. The original synthetic 
approach involved a one-pot protecting group removal and reductive amination of the N-Cbz 
protected amine.1 Subsequently, the N-amine was cyclized with the -carboxylic acid to yield 
the desired product. Typically, this route requires juggling of protecting groups and there is 
typically no stereochemistry incorporated off of the N-amine position (R1 in Figure 1B). The 
number of patent references on this generalized structure demonstrates the pharmaceutical 
usefulness of this lactam backbone.  One sought-after usage of Freidinger lactams, beyond its use 
as a small molecule scaffold, is its potential use in developing conformationally constrained 
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peptidomimetic compounds.2 In the early 1980’s, Freidinger incorporated his lactam scaffold 
into luteinizing hormone-releasing hormone to produce a conformationally constrained mimic, 
which displayed biological activity better than the parent compound.3 The team found that the 
conformational constraint mimicked the beta turn of the endogenous luteinizing hormone-
releasing hormone when bound to its receptor. This result was an early example that sparked 
interest in development of conformationally constrained peptides. More recently, other 
researchers have designed peptidomimetic compounds containing Freidinger lactams that 
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Natural Product  (Discovered 2008)
Potent Cytotoxin - shown potential in 
usages for lung cancer, neuroblastoma, 
infectious diseases (HIV, HCV)  
Figure 3.2. Select pharmaceutically relevant examples of molecules with Freidinger-like -




Symplocamide A, (Figure 3.2) discovered in 2008, has displayed high selectivity for 
inhibition of serine proteases and potent activity against cancer cells and neuroblastoma cells.5 
Palonosetron (Figure 3.2), used in the prevention and treatment of chemotherapy-induced 































Figure 3.3. Original synthetic strategy to Freidinger lactam.1  
The current synthesis of Freidinger lactams (Figure 3.3) currently has low yield and 
requires intermediate purification.  The current strategy also limits the functionality of the lactam 
ring because the functionalization of the N-amine is performed from reductive amination with 
an aldehyde that cannot be chiral at the carbon that becomes bonded to the N-amine (the carbon 











































Figure 3.4. Proposed approach to Freidinger lactam structures with incorporated chirality off N-
amine.  
Our propsed approach (Figure 3.4) begins with commercially available Fmoc-ornithine 
and converts the side-chain amine into a bromide utilizing diazotization conditions and having 
the bromide nucleophile in solution simultaneously to displace the unstable aliphatic diazonium. 
From the bromide intermediate (2), (S)-5-Bromo-2-[9H-fluoren-9-
yl)methoxycarbonylamino]valeric acid, any chiral amine could be used to displace the bromide 
and a subsequent cyclization leads to the desired lactam ring scaffold. From there, the Fmoc 
protecting group could be removed if reacting that nitrogen is sought after, but further 
derivatization beyond the N-Fmoc-protected N-lactam is beyond the scope of the work 
presented here. However, the strategies presented herein could be utilized to develop larger 
molecules such as symplocamide A (Figure 3.2). Furthermore, our proposed approach allows for 
incorporation of chirality on the lactam N carbon and increases the versatility of the framework 




COMPARABLE APPROACHES (LIT.)  
 
Figure 3.5. Comparable synthetic routes to gamma-, delta-, and epsilon-lactams.6, 7, 8, 9 A) 
Thioether route from Int. J. Pept. Protein Res. 1990, 35, 481-494. B) Photoredox route from J. 
Org. Chem. 1997, 62, 654-63. C) Reductive amination route from J. Org. Chem. 2005, 70, 5946-
5953. D) Reduction to alcohol and subsequent conversion to bromide route from Org. Lett. 2013, 
15, 448-451.  
 
There are other routes depicted in literature (Figure 3.5) that form lactam rings of 
varying size (5 to 10-membered rings). The reductive amination route to attaching an amine to 
the side-chain prior to cyclization is still in use today.10 However, there are other notable 
attempts that have not gained wide acceptance, such as using ring-closing olefin metathesis, 
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which leaves an unsaturated double bond within the newly formed lactam ring (a potentially 
useful functionality for further ring functionalization).11 There has also been interest by others in 
improving the synthetic route to Freidinger lactams using a combination of microwave 
irradiation and solid-phase synthesis (Wang resin).12 Nevertheless, this solid-phase synthesis 
approach would be very atom uneconomic for larger scale synthesis.  
DIAZOTIZATION OF ALIPHATIC AMINES (LIT.) 
 
Figure 3.6. Literature study of products formed from diazotization of aliphatic amines 
Reference table: J. Am. Chem. Soc. 1965, 87, 5790-5791.13 
Literature precedent shows that under diazotization conditions, aliphatic amines produce 
an unstable diazonium salt that either quickly degrades into an alkene or is converted into an 
alkyl halide or alcohol through nucleophilic displacement (Figure 3.6). These results 
demonstrate that in some cases a haloacid, such as HCl, is enough of a halogen source to allow 
for substitution. Furthermore, solvent selection plays an important role in the product outcome.  
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Additional literature precedent provides us with examples that diazotization is in fact 
possible in the presence of an adjacent carboxylic acid (Figure 3.7).14, 15 However, in our 
designed route, our amine of interest is not on the -carbon, but instead on the -carbon position. 
And surprisingly, even under the highly acidic reaction conditions, there is even retention of a 
boc-protecting groups on amines and t-butyl protecting groups on carboxylic acids.14, 15  
 
Figure 3.7. Literature precedent for the successful diazotization of aliphatic amines. 
 
MATERIALS AND METHODS 
General 
Diazotization procedure. Desired aminocarboxylic acid (1 equiv.) was dissolved in HBr 
(16-48%) with sodium bromide (7.5 equiv) and cooled to 0 oC. A solution of sodium nitrite (3 
equiv.) and sodium bromide (2.5 equiv.) in water was added dropwise to the reaction at 0 oC. 
The reaction mixture stirred for 1-18 h. The resulting oil was extracted with DCM (3x). The 
DCM extracts were combined, washed with water (1x), saturated aqueous sodium chloride 
solution (3x), dried over sodium sulfate, and concentrated.  
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Column chromatography was performed on silica gel 60, particle size 0.040-0.063 mm.  
1H and 13C NMR spectra were recorded on either a Bruker or JEOL spectrometer (500 MHz). All 
collected MALDI mass spectra for this chapter can be found in Appendix C. 
Materials 
Trifluoroacetic acid (TFA), zinc acetate (Zn(OAc)2), acetonitrile (ACN) were purchased 
from Sigma (St. Louis, MO).  Concentrated hydrochloric acid (HCl) obtained from Fisher 
scientific. Granular sodium nitrite (NaNO2) obtained from Macron chemicals (Center Valley, 
PA). Hydrobromic acid 48% (HBr) obtained from EMD Millipore (Billerica, MA). Methanol 
(MeOH) and sodium sulfate (Na2SO4) obtained from VWR International (Radnor, PA). Sodium 
bromide (NaBr), sulfuric acid (H2SO4) obtained from J. T. Baker (Center Valley, PA). 4-
methylmorpholine, sodium borohydride 98% (NaBH4) obtained from Alfa Aesar (Haverhill, 
MA). Sodium cyanoborohydride (NaCNBH3) obtained from AK Scientific. 
Tetrakis(triphenylphosphine) palladium (0) 99% ((Ph3P)4Pd) obtained from Strem Chemicals 
(Newburyport, MA). (S)-(-)-1-phenylethylamine obtained from TCI America (Portland, OR). 
N,N’-carbonyldiimidazole (CDI), triflic anhydride (Tf2O) obtained from Oakwood Chemicals 
(Estill, SC). Thionyl chloride (SOCl2) obtained from TCI America (Portland, OR). Fmoc-
Glu(OtBu)-OH obtained from Aapptec (Louisville, KY). N,N’-diisopropylethylamine (DIEA), 
Nα-Fmoc-Nδ-Boc-L-ornithine obtained from Chem-Impex International (Wood Dale, IL). All 
Fmoc-protected amino acids were used without further purification. All reagents and organic 





Molecular weight was obtained from MALDI mass spectrometry using Bruker 
Daltonics/Omniflex MALDI mass spectrometer.  Samples were prepared by mixing 1.5 μL of 
aliquot with 1.5 μL of the matrix solution, a saturated solution of α-cyanohydroxycinnamic acid 
in acetone with 0.3% TFA.  One microliter of the sample mixture was spotted unto the sample 
plate and dried by vacuum prior to mass spectrometry.  Data for 2 ns pulses of the 337 nm 
nitrogen laser were averaged for each spectrum in a linear mode, and positive ion TOF detection 
was performed using an accelerating voltage of 25 kV. All collected MALDI mass spectra for 
this chapter can be found in Appendix C. 
  
RESULTS AND DISCUSSION 
If the proposed route is to be successful, one of the first vital questions that needed to be 
understood was whether the Fmoc-protected amine was stable to diazotization conditions. This 
was tested by placing Fmoc-Ala-OH in diazotization conditions (NaNO2, HBr, NaBr, 0 
oC) for 
two hours and monitoring the starting material by 1H NMR after 20 minutes, 1 hour, 2 hours, and 
24 hours (Figure 3.8).  The conclusion of the experiment was that the Fmoc is stable under these 
conditions for at least 2 hours because there was no presence of the distinctive CH2 singlet from 






Figure 3.8. 1H NMR time course analysis of fmoc stability under diazotization conditions. 
Reagents and conditions: a) NaNO2, NaBr, 16% HBr, 0 
oC. 
The next potential synthetic problem that needed investigation was two-fold: 1) would 
the bromide displace the unstable diazonium that is formed to yield the alkyl bromide; and 2) 
how stable is the diazoalkylcarboxylic acid and/or the subsequently formed bromoalkyl 
carboxylic acid. These issues were tested by taking linear amino acids with varying carbon chain 
lengths (4-6) and exposing them to diazotization conditions to see whether or not intramolecular 
























n = 1, 2, 3, 4




Figure 3.9. Summary of initial diazotization results. Reagents and conditions: a) NaNO2, NaBr, 
16% HBr, 0 oC. 
 
Upon exposure of 6-aminoheptanoic acid to diazotization conditions (Figure 3.9, entry 
4), 1H NMR spectrum of the product mixture showed 6-bromohexanoic acid as the major 
product.  There was a minor –O-CH2 triplet peak that gave indication of a small amount of ε-
caprolactone formation. Diazotization of 5-aminovaleric acid was accomplished in the presence 
of high [Br-]; 10 equivalents compared to the 5 equivalents previously used (Figure 3.9, entry 
3).  The lactone was only 6.5% of the product mixture so there was 93.5% bromovaleric acid 
formation.  The hypothesis moving forward was that increasing the concentration of reagents 
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would aid formation of the bromoacid. The γ-aminobutyric acid was exposed to diazotization 
conditions (Figure 3.9, entry 2) and almost equal amounts of 4-bromo-n-butyric acid and 
lactone were observed in the product mixture, 60:40 percent product mixture respectively. In the 
case of β-alanine (Figure 3.9, entry 1), β-propiolactone was observed as the major product in 
the product mixture with 3-bromopropionic acid as the minor product, which is likely due to the 
close proximity of the short-lived diazo group to the carboxylic acid position. This close 
proximity may make it more likely to form the ring even though the 4-membered ring would be 







Scheme 3.1. Reaction of 5-bromovaleric acid with (S)-(-)-1-phenylethylamine. Reagents and 
conditions: a) ACN, Na2SO4, 18-72 h, r.t.  
 
A reaction of the bromovaleric acid with (S)-(-)-phenylethylamine (Nspe) yields the 
desired -lactam structure as shown in Scheme 3.1. This reactivity supports the presence of the 
bromoacid as the intermediate that was formed from the diazotization.  
Since the diazotization was successfully performed on simple aliphatic aminoacids 
(Figure 3.9) and the conversion of the bromoalkyl carboxylates to the desired lactams was 
demonstrated, the next step toward the desired Freidinger-like lactams was to test -
aminocarboxylic acids that have a protected -amine substituent. Fmoc-protected amino acids, 
such as Nα-Fmoc-Nδ-Boc-L-ornithine, are commercially available and provide an excellent 
starting point for the formation of -lactam rings via our proposed diazotization route. 
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Since the diazotization occurs under acidic conditions, it was hypothesized that the Nδ-
Boc could be removed in one-pot with the desired subsequent diazotization. Surprisingly, the 
attempted removal of N-Boc from Nα-Fmoc-Nδ-Boc-L-ornithine in situ while performing 
diazotization yielded no removal of Boc and no desired product and the Boc-protected starting 
material was recovered from 16% HBr (aq).   
 
entry R1 R2 Product % Yield
5a* not bromide -
5b not bromide -
5c not bromide -
5d not bromide -
 
Figure 3.10. Diazotization attempts yielded no desired product. Reagents and conditions: a) 5 eq 
NaNO2, 20 eq NaBr, 48% HBr, 0 
oC. *This reaction was tested under a variety of conditions 
(e.g. NaNO2, H2SO4, NaBr, THF:H2O, -80 
oC; NaNO2, TsOH, NaBr, THF:H2O, -40 
oC.) and 
yielded similar results under each.  
 
Fmoc-Orn(NH2)-OH, 5a, obtained from Boc deprotection of N
α-Fmoc-Nδ-Boc-L-
ornithine under 3:1 (v/v) TFA:H2O conditions was difficult to redissolve in MeOH, acetone, and 
D2O. However, 
1H NMR of the sample was obtained in D2O. A reaction of Fmoc-Orn(NH2)-OH 
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under diazotization conditions (Figure 3.10, entry 5a) yielded an unclear and crowded 1H NMR 
of the crude reaction mixture. MALDI-mass spectral analysis of the reaction mixture was 
complex and indicated that multiple species were present, yet closer analysis suggested that the 
lactone product formed (m/z 337) in competition with the desired bromide (MW = 418.28, m/z 
438 [M+H]+ and 440– [M+Na]+ for bromine isotopes 79 and 81). The diazotization reaction 
initially yielded promise, but replication and optimization efforts were unsuccessful. Further 
attempts at forming the brominated product gave MALDI-mass spectrum peaks around the m/z 
ratio expected for the product if two water molecules were closely associated with the desired 
product (m/z 453.7 and 455.7 – for bromine isotopes 79 and 81). Unfortunately, however, the 
bromide nor the lactone were the major product of the initial reaction and were present in 
negligible amounts after purification of the reaction mixture. Further NMR analysis did not help 









Molecular Weight: 337.38Molecular Weight: 418.29  
Scheme 3.2. Small-scale test reaction performed to help elucidate whether the bromoacid 
starting material was formed through diazotization.  
A subsequent attempt at the diazotization of the amine showed the presence of a 
brominated product (amongst other peaks) in the MALDI spectrum, with the correct isotopic 
distribution of peak m/z ratios to what is expected for the desired product containing a bromine 
atom. A small-scale test reaction of the material from that reaction in the presence of a base, such 
as DIEA, should cyclize to form the lactone (Scheme 3.2) and the change in mass along with the 
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difference in isotopic distribution would be detectable by MALDI-mass spectral analysis. The 
result of this test reaction suggested that detectable amounts of the desired product were present, 
however they were overshadowed by a [M+60]+ product peak which support the notion that the 
desired product was not the major component of the diazotization reaction.  
 
With the knowledge that there are detectable amounts of lactone occurring in the 
reaction, the hypothesis moving forward was that protecting the carboxylic acid as a methyl ester 
will increase the stability of the bromoacid product and decrease any potential cyclization 
(Figure 3.10, entry 5b). Methyl ester formation and Nδ-Boc deprotection of Nα-Fmoc-Nδ-Boc-
L-ornithine proceeded in excellent yield using thionyl chloride in MeOH. The liberated amine 
was subjected to the optimized diazotization conditions and the product mixture was analyzed 






Figure 3.11. NMR analysis of starting material (bottom) and crude product mixture (top) from 
attempted diazotization of Fmoc-Orn(NH2)-OMe. CH2 peak shift observed in crude product. 
Multiple attempts suggest a shift in peak position.  The chemical structure on the top spectrum is 
that of the desired product. 
 
NMR analysis of the starting material and product (Figure 3.11) showed a downfield 
shift in the CH2 peak adjacent to the side-chain amine suggesting an electron withdrawing group 
was formed. While it was unclear from NMR and a MALDI-mass spectrum analysis if the 
product was the result of NH2 being converted into Br, a subsequent reaction with a nucleophilic 
amine to displace the bromide would support the presence of product from a successful 
diazotization; thus, (S)-(-)-phenylethylamine was used (Scheme 3.3). However, upon analysis of 
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this test reaction, the desired lactam product was not conclusively seen. If the desired -lactam 
were present, it looked like an impurity (by NMR) in a different product. These results suggest 
that the product after diazotization is not likely the desired bromide and that the CH2-NH2 shift 
observed by 1H NMR was likely caused by some other (as of yet unidentified) reactivity of the 
aliphatic amine. 
 
Scheme 3.3. Attempted synthetic route to the lactam product. reagents and conditions: a) SOCl2, 
MeOH, Quant. b) 5 eq NaNO2, 20 eq NaBr, 48% HBr (aq), H2O, 0 
oC. c) (S)-(-)-
phenylethylamine, DIEA, 75 oC, 4 hr or no DIEA. 
 
Instead of the desired product being formed from the reaction of (S)-(-)-phenylethylamine 
with the diazotization product (Scheme 3.3, reaction c), the major product displays distinct 1H 
NMR (Figure 3.12) and IR spectra that has yet to be matched to a molecular structure. This 
result indicates the presence of an unknown major product that would be the result from an 
unknown sequence of chemical reactions. Elucidation of this unknown product would shed light 
on the type of reactivity occurring under these chemical conditions and could potentially lead to 
the development of a new synthetic reaction. Further investigation of the structure of this 
unidentified product were outside the scope of this project and were not attempted beyond trying 





Figure 3.12. 1H NMR spectrum of the unidentified major product after diazotization and Nspe 
addition.  
 
Crystallization attempts: Various methods were attempted to form crystals of the 
purified unknown product that was formed from the reaction: 1) slow evaporation from 
dichloromethane alone at room temperature. This resulted in a powder along the walls of the 
culture tube used; 2) layering hexane atop product dissolved in dichloromethane at room 
temperature. This resulted in some powder substance along the walls of the culture tube and most 
of the powder at the bottom of the tube; 3) from a slow evaporation of a DCM/MeOH solvent 
mixture at room temperature. This resulted in the same powder formation as that from 
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uncharged analogueindole-3-acetic acid choline ester  
Figure 3.13.  Intramolecular cation-pi interaction.  Adapted from reference:  K. Aoki, et al., J. 
Chem. Soc. Chem. Commun. 1995, 2221-2222.16  
 
One potential issue (amongst other possibilities) could be the presence of a pi-cation 
interaction (Figure 3.13) in solution or potentially nucleophilic carbonyl adjacent to N in fmoc 
that interferes with the diazotization process. One potential way to test if the diazotization is 
disrupted by an interaction with the pi-system of the Fmoc-protecting group is to use a different 
protecting group on the alpha amine. So, the hypothesis for subsequent reactions (Figure 3.10, 
entries 5c-5d) was that if the presence of Fmoc is hindering the diazotization reaction, then 
replacing Fmoc (or NH-C(O)-) should restore the desired reactivity to what was observed when 
there was no alpha substituent.  
If the pi-cation interaction was the hinderance for the reaction, then replacing Fmoc 
would remove the aromatic rings and allow the reaction to proceed as it did with 5-aminovaleric 
acid. However, when the substitution on the N-amine was changed to mimic a piperidine ring 
(Figure 3.10, entry 5c), the resulting product mixture under the conditions tested, did not 
display the desired promine product. To remove the lone pair of electrons from consideration as 
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a possible source of interference, the N-amine was trimethylated to the ammonium (Figure 
3.10, entry 5d) yet the result remained unchanged; no desired bromine product was evident in 
the product mixture. It remains unclear as to why the N-aliphatic amine diazotization and 
subsequent displacement with bromide worked in the absence but not the presence of an N-
amine.  
 
Scheme 3.4. Diazotization of ornithine leads to a mixture of products.17  
In the late 1980’s, it was observed that one of the potential products from subjecting 
ornithine to diazotization conditions is the amine being substituted for an alcohol (Scheme 
3.4).17 This would arise from the displacement of the diazonium by a water molecule, which is in 
high concentration as the reaction solvent. This hydroxyl substitution could theoretically be one 
of the products observed in the reactions tested within this chapter, however efforts were 
attempted to increase the bromide ion concentration to compete with water for nucleophilic 
displacement of the diazonium. It should also be noted that if a hydroxyl was formed from the 
diazotization of the N-amine, then this would also cause a 1H NMR shift in the CH2 protons 
(Figure 3.11) due to the increased electronegativity of the oxygen atom compared to the 
nitrogen. However, if the alcohol was formed, the subsequent reaction with (S)-(-)-
phenylethylamine would not explain the 1H NMR that was observed for the major product 









































3) Deprotection  
Figure 3.14. Proposed approach to Freidinger lactam via activation and reduction of secondary 
amide to secondary amine.  
 
Based on the unsuccessful results observed from the attempted aliphatic amine 
diazotization, an alternative route was theorized for further investigation to the desired lactam 
framework (Figure 3.14). Starting from commercially available N-Fmoc-Glu(OtBu)-OH, an 
allyl protection of the -carboxylic acid and subsequent acidic deprotection of the side-chain 
tert-butyl liberates the side-chain -carboxylic acid to form N-Fmoc-Glu(OH)-OAll. N-Fmoc-
Glu(OH)-OAll in the presence of CDI and a chiral amine forms the desired amide bond. A 
reduction of the secondary amide to the secondary amine allows for the eventual cyclization to 
form the -lactam with chirality off of the N-amine. The key step in this procedure is the 
reduction of the secondary amide to the secondary amine because traditional chemistry is not 
suitable to perfom this transformation on our substrate selectively in the presence of a carbamate 




Figure 3.15. Select examples of literature precedent for reduction of amide to amine.18, 19, 20 Top 
– Reduction of secondary amides via Tf2O activation and subsequent reduction.  Bottom – 
Reduction of tertiary amides via zinc acetate-catalysis.  
 
Traditionally, researchers have used strong reducing agents such as LiAlH4 in order to 
reduce amides to amines. However, this reduction approach would not only reduce the amide and 
ester functional groups, but it would also deprotect the Fmoc amine, making this synthetic route 
implausible for our goals. More recently, there have been literature examples of amides being 
reduced in one pot under more mild conditions (Figure 3.15) with either: 1) triflic anhydride 
activation and NaBH4;
18, 19, 21 or 2) transition metal-catalyzed.20, 21 Therefore, various conditions 
were attempted in order to determine the feasibility of this synthetic approach to the Freidinger-




Figure 3.16. Attempted routes to reduce the secondary amide to a secondary amine using either 
Tf2O/hydride or Zn-mediated transfer hydrogenation.  
 
The reaction conditions that were selected to test for secondary amide reduction (Figure 
3.16) were conditions that had been shown to work in other chemical systems within the 
literature. Three of the routes attempted utilize Tf2O to first activate the secondary amide into the 
presumed imidol triflate intermediate prior to reduction with a hydride source. These reactions 
have been reported in other systems to proceed well at 0 oC to room temperature.18  The two 
small-scale reaction routes that introduced DIEA with Tf2O for the activation of the amide led 
mainly to unidentified products with higher mass than that of starting material and product. The 
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route that did not have a base present during the activation step proceeded cleanly to the desired 
amine reduction product. The Tf2O/NaBH4 amide reduction reaction demonstrated 
chemoselectivity for the amide in the presence of an ester and carbamate.  
A fourth set of conditions was chosen that utilized Zn-catalysis in the presence of a 
trialkyl silane. Literature precedent of similar reaction conditions utilized Zn(OAc)2 as the zinc 
source and triethoxysilane.20 Researchers did note that at room temperature, other silanes did not 
react, but some silanes (PhSiH3, Ph2SiH2, and (EtO)2MeSiH gave excellent yields for the 
reduction of their model system (N,N-dimethylbenzamide) at 65 oC. I chose to utilize 
triisopropylsilane (TIPS) because 1) to my knowledge others have not reported on its feasibility 
under these reaction conditions and 2) it was readily accessible. Unfortunately, there was no 
reactivity at all under these Zn/TIPS conditions as assessed by MALDI-mass spectral analysis 
and the starting material was recovered. This result shows that TIPS has similar reactivity to 
triethylsilane which was tested in literature.18   
 
Scheme 3.5. Attempted synthetic route to desired Freidinger lactam via Fmoc-Glu(OtBu)-OH 
using O-Allyl ester protection and reduction of amide to amine. Reagents and conditions: a) 
allylbromide, DIEA, reflux, 1h. b) TFA:DCM 3:1 (v/v), 1.5 h, r.t. c) (s)-(-)-1-Phenylethylamine, 
CDI, DIEA, DCM. d) Tf2O, DCM, 0
oC, 30 mins, NaBH4, THF:DCM (2:1), r.t., 1 h. e) 
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(Ph3P)4Pd, N-methylmorpholine, THF (dry), 18h. This reaction was unsuccessful—failing to 
produce the desired product. f) CDI, DCM, 2h. This reaction was unattempted. 
Once it was shown that the amide could be reduced efficiently to the amine, the material 
still needed to be cyclized to form the desired lactam product (Scheme 3.5). Cyclization could 
potentially occur via two different pathways: 1) the allyl ester is deprotected to liberate the 
carboxylic acid prior to using a coupling reagent to form an amide bond with the side-chain 
amine; or 2) the amine could potentially displace the O-allyl in the presence of base with or 
without heating. The side-chain secondary amine is known, from the original Freidinger lactam 




















Scheme 3.6. Cyclization of Fmoc-Orn(Nspe)-OAll to the desired -Freidinger-like lactam. 
Reagents and conditions: DIEA, NaHCO3, DMF, 90-100 
oC, 8h.  
 
Alternative reaction conditions were tested on a small scale to go from the Fmoc-
Orn(Nspe)-OAll to the -lactam that avoided the usage of Pd-catalysis (Scheme 3.6). These 
initial efforts demonstrated that in the presence of DIEA and NaHCO3, Fmoc-Orn(Nspe)-OAll 
could be cyclized without first deprotecting the allyl ester to the free carboxylic acid and 
subsequently utilizing a coupling reagent as initially proposed.  
    
Conclusions 
In summary, the current synthetic route to Freidinger lactams is typically low yielding 
and very limited in functionalization. We sought a standard reagent that could be readily used to 
create Freidinger lactams incorporating Nδ-chirality. Instead of needing to synthesize a novel 
reagent (2) ((S)-5-Bromo-2-[9H-fluoren-9-yl)methoxycarbonylamino]valeric acid), we have 
instead demonstrated the more easily accessible Fmoc-Glu(OH)-OAll to function in that 
capacity. The application of amide to amine methodology that was developed herein could be 
useful in forming Freidinger lactams with defined stereochemistry as a building block to more 
complex small-molecules or even find usage in the design of conformationally constrained 
peptidomimetics. The strategy that was developed here proceeds in very good yields and allows 
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DESIGN AND DEVELOPMENT OF POTENTIAL ANTIMICROBIAL PEPTOIDS FOR 
ENDOSCOPE STERILIZATION  
 
Introduction 
Endoscopes come in various types and are used in 700,000 operations annually.1 At a 
cost of $40,000-$80,000 per endoscope,1 they need to be rapidly cleaned between patients. 
However, the FDA issued a report saying that even under duodenoscope manufacturer 
reprocessing instructions, infections could still occur.2  
The emergence of MDR bacterial strains such as MRSA, which have led to post-op 
infections due to the inability to effectively sterilize surgical instruments, such as 
duodenoscopes, between procedures has become a major problem for health systems across the 
United States.3, 4 Additionally, outbreaks of carbapenem-resistant enterobacteriaceae (CRE), 
such as Escherichia coli and Klebsiella pneumoniae, related to duodenoscopes have resulted in 
patient infections and even deaths.5   
The traditional FDA-approved sterilization method for endoscopes involve automated 
endoscope reprocessors (AER). The first step in sterilizing an endoscope centers on submerging 
the device in a liquid basin with a high-level disinfection solution (HLD), containing chemicals 
such as glutaraldehyde, hydrogen peroxide, or peracetic acid, for example. The endoscope 
channels are connected to the AER and the HLD is circulated under pressure through the device 
for roughly 30 minutes. The AER then rinses the scopes with water, removing the toxic HLD 
solution, and washed again with ethyl or isopropyl alcohol and dried with air.6 Other methods are 
also used to sterilize endoscopes including ethylene oxide (EO), ozone, and gamma/electron 
beam irradiation (extremely rare). EO sterilization is an effective way to sterilize endoscopes,7 
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but has been found to be hazardous to patients, staff, and the environment. There is significant 
risk associated with handling and exposure to the highly flammable gas. EO sterilization has also 
been shown to be a relatively expensive process for health systems requiring significant 
infrastructure investment.8 Gamma and electron irradiation has been shown to damage some 
medical devices.9  
AERs are used to clean duodenoscopes—complex endoscopes with many working parts 
that are used to treat problems in the pancreas and bile ducts. Recently, the FDA reported 
infections occurring in patients who underwent procedures with duodenoscopes that were 
reportedly sterilized with AERs using HLD solutions before the procedures began.10 Bacterial 
species can become resistant to the solutions used in AERs. For example, it was shown that 
certain strains of Mycobacteria spp. developed a resistance to aldehyde-based HLDs11 and 

















































Figure 4.1. Structure of omiganan—a cationic antimicrobial peptide. 
 
The short half-life and poor oral bioavailability of antimicrobial peptides are major 
challenges for why they tend to fail late-stage clinical trials. While there are examples of 
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antimicrobial peptides that have made it far in clinical trials, such as the cationic peptide 
omiganan (Figure 4.1), they have not effectively shown the ability to meet clinical endpoints.  
Peptoids (N-substituted glycine oligomers)—a class of peptidomimetics—are similar to 
α-peptides in structure (Figure 4.2), but the side chains are attached to an Nα-amide nitrogen 
backbone as opposed to the Cα-carbon, making them highly resistant to protease activity and 
potentially suitable to succeed where antimicrobial peptides are currently failing.12, 13  
 
 
Figure 4.2. Structural difference between the peptide and peptoid backbone.  
 
Multiple groups have shown that peptoids are powerful antimicrobial agents in vitro, with 
potential to combat multi-drug resistant (MDR) bacterial strains.14, 15, 16 There are multiple ways 
peptoids act to disrupt bacterial cells, but they are generally thought to penetrate the bacterial cell 
wall and membrane, leading to pore formation and leakage of the cell.16 Similar to antimicrobial 
peptides,17 the combination of amphiphilic, cationic, and hydrophobic side chains are thought to 
play a role in this disruption by interacting with the anionic bacterial membrane.18, 19 Peptoids 
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Literature Precedent - Antimicrobial Peptoids:
Our Proposed Antimicrobial Library Structures:
n
 
Figure 4.3. Literature precedent and a general proposed structure for the design of peptoid trimer 
library.  
 
Here, we synthesize a potentially potent class of novel antimicrobial peptoids in a way 
that is facile and economically feasible—with the expectation that, based on literature 
precedence of similar molecular structures (Figure 4.3), they will effectively sterilize sensitive 
surgical instruments, like duodenoscopes. Both peptoid trimers and dimers were synthesized. 
 
MATERIALS AND METHODS 
General 
Column chromatography of 27-33 was performed on silica gel 60, particle size 0.040-
0.063 mm.  1H and 13C NMR spectra of 27-33 were recorded on either a Bruker or JEOL 
spectrometer (500 MHz). All characterization spectra can be found in Appendix D. 
Materials 
Trifluoroacetic acid (TFA) and acetonitrile (ACN) were purchased from Sigma (St. 
Louis, MO).  Bromoacetic acid, N,N’-diisopropylethylamine (DIEA) was obtained from Chem-
Impex International (Wood Dale, IL). Dimethylformamide (DMF), 2-Phenylethylamine, 1-
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hexylamine, 1-octylamine, 1-dodecylamine, N,N-diethylenediamine, 1,3-diaminopropane, and 
diethylenetriamine were obtained from Alfa Aesar (Haverhill, MA). 3,3-diphenylpropylamine 
was obtained from AK Scientific. 4-Chloromethylbenzoyl chloride was obtained from TCI 
America (Portland, OR). Rink Amide Resin was obtained from Aapptec (Louisville, KY). All 
reagents and organic solvents used were at least ACS grade.   
Peptoid Synthesis 
Solid-Phase Synthesis. There are several ways to synthesize peptoids in lab. One solid-
phase synthesis of peptoids utilizes reductive alkylation of glycine with an aldehyde or ketone to 
create an N-alkylated glycine derivative;21 the monomer approach, which features the sequential 
coupling of typically Fmoc-protected N-substituted glycine molecules using standard peptide 
synthesis technique;22 and the sub-monomer approach,12 which is most similar to our approach 
shown here. Peptoid synthesis was done on 100 mg Rink amide resin. Swelling and deprotection 
of the Rink amide resin begins with the addition of dimethylformamide (DMF) followed by 
stirring for 1 minute. 20 % 4-methylpiperdine is then added for initial deprotection and the 
solution stirs for 1 minute. Following the addition of each substance, 3 washes with 1 mL of 
DMF were performed. Once the initial deprotection is performed, residues can be added. 
Addition of residues to the resin follows a two-step process: acylation followed by an SN2 
displacement reaction. Prior to adding the first amine, an acylation reaction occurs by adding 938 
µL of 0.4 M BrAA in combination with 62 μL of diisopropylcarbodiimide (DIC) (to a final 
concentration of 0.4 M DIC). Displacement then occurs as the amine of choice (R2—NH2, 0.5 M 
in DMF) displaces the halide (—Br) to form the N-substituted glycine residue (SN2 reaction). 
The process can be completed as many times as is necessary to achieve a peptoid of the desired 
length with the appropriate structure. Here, we performed the reaction 3 times to create a peptoid 
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trimer and also synthesized peptoid dimers containing an aromatic residue using slightly 
modified procedures. Once the trimer is created, the peptoid must be cleaved from the resin. To 
do this, a 95% trifluoroacetic acid (TFA):2.5% triisopropylsilane (TIPS):2.5% H2O solution was 
used to cleave the peptoid from the resin. The solution was then vortexed for 30 minutes and 
dried using N2 gas. Following the drying, the samples were re-dissolved in a 50:50 mixture of 
acetonitrile and water and were analyzed using MALDI and HPLC.  
 
Solution-Phase.  
Synthesis of p-(chloromethyl)phenyl][2-(diethylamino)ethylamino]formaldehyde (26). A 
stirring solution of chloromethylbenzoyl chloride (3.00 g, 15.9 mmol) in DCM was cooled to 0 
oC prior to adding N,N-diethylethylenediamine (2.24 mL, 15.9 mmol).  The reaction was allowed 
to warm to room temperature and stirred for 1 h before concentrating under vacuum to obtain 
crude 26 (quant.). NMR analysis of the crude material revealed it was pure enough to use in the 
subsequent step without further purification.  
General Procedure for the Synthesis of (27-31). A solution of 26 (1 equiv.) and desired 
amine (0.5 equiv.) was made in ACN with stirring at room temperature. DIEA (1 equiv.) was 
added to the reaction mixture. DMF and KI (1 equiv.) which was then stirred 18 h. The reaction 
was quenched with excess H2O and the product extracted with DCM (3 x). All products were 
purified using silica via column chromatography with a DCM:MeOH gradient as the mobile 





Molecular weight was obtained from MALDI mass spectrometry using a Bruker 
Daltonics/Omniflex MALDI mass spectrometer.  Samples were prepared by mixing 1.5 μL of 
aliquot with 1.5 μL of the matrix solution, a saturated solution of α-cyanohydroxycinnamic acid 
in acetone with 0.3% TFA.  One microliter of the sample mixture was spotted into a cell of the 
sample plate and dried prior to mass spectrometry.  Data for 2 ns pulses of the 337 nm nitrogen 
laser were averaged for each spectrum in a linear mode, and positive ion TOF detection was 
performed using an accelerating voltage of 25 kV. 
 
Results and Discussion 
 
Scheme 4.1. Ronald Zuckermann’s submonomer approach to peptoid synthesis. Elongation 
entails iterative haloacetylation (with a haloacetic acid) and nucleophilic displacement (with a 
primary amine, R-NH2) steps. The varying of R-groups on the amine allow for incorporation of 
chemical diversity into the peptoid chain.  
 
In the 1990’s, Ronald Zuckermann developed a submonomer approach to peptoid 
synthesis that is still in use today (Scheme 4.1).12 These traditional peptoid synthesis methods 
utilize coupling times of 1.5-3 hours per residue.12, 23 However, our lab has developed a synthetic 
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approach to peptoid oligomers that utilizes 1 minute peptoid couplings that drastically reduce the 
time necessary for the synthesis of these molecules.24   
 
Section 4.1: Trimers with aliphatic backbone. 
Herein we designed the peptoid trimers (Figure 4.4) with 3 different amine-based side-
chains (cationic, aliphatic, aromatic). The cationic chain was used due to its potential as a 
bacterial cell membrane-disrupter. The aliphatic and aromatic structures were used in order to 
increase the lipophilicity of the peptoid molecules. Notable differences in toxicity have been 
noted in the literature depending on whether hydrophobicity results from aliphatic or aromatic 
side chains.15 We created many different structures, each one with a different combination of 
cationic, aliphatic, and aromatic side chains. The sidechains could be further fine-tuned if 
necessary, but the overall experimental goal is to bracket potential extremes, primarily in 
hydrophobicity, in a Design-of-Experiemtns-type approach. These specifc structures or second-
generation ones derived from them could potentially act alone or in combination as potent agents 
against the wide variety of membrane-containing targets that need to be sterilized from 
endoscopes-human cell, yeast, gram-positive and –negative bacteria, spores, HIV, and 
hepatitis—eventually leading to the development of a new solution for the sterilization of 
endoscopes with the use of AERs.  
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entry R1	(Cationic) R2	(Aromatic) R3	(Aliphatic)
1 NH2 Ph C6
2 NH2 Ph C8
3 NH2 Ph C12
4 2NH2 Ph C6
5 2NH2 Ph C8
6 2NH2 Ph C12
7 NH2 2Ph C6
8 NH2 2Ph C8
9 NH2 2Ph C12
10 2NH2 2Ph C6
11 2NH2 2Ph C8
















(C6) (C8) (C12)(Ph) (2Ph)(NH2) (2NH2)
 
Figure 4.4. Design and structure of the peptoid trimers synthesized in this work.  
 
To test whether changing the order of the residues matters, the two control sequences 
below were also synthesized (Figure 4.5). If the reverse-order sequences 13 and 14 have 
markedly different activity than their analogs 4 and 12, respectively, then additional sequences 
altering the residue order will be synthesized and tested. 
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Figure 4.5. Two sequences designed to evaluate whether the residue order is important (13 is an 
analog of 4, 14 is an analog of 12). 
 
There have been some recent examples where increasing the hydrophobicity of cyclic 
antimicrobial peptoids have resulted in lower MIC’s (Figure 4.6).25 It was observed that when 
the propyldiphenyl was used versus a benzyl in a comparable structure, the peptoid was much 
more potent (Figure 4.6). Similarly, when the cationic chain was one carbon shorter, the 
diphenylethyl substitution was a more potent antimicrobial agent than the phenylmethyl (Figure 
4.6). These results suggest that amongst the structures synthesized in our work, the 




























n = 1, m = 1
n = 0, m = 0 < 8
n = 1, p = 0












Figure 4.6. Antimicrobial activity of cyclic peptoids found in literature. aEur. J. Org. Chem. 
2013, 3560-3566.b Biopolymers 2014, 103, 227-236. 
 
Researchers have shown more recently that by taking a linear peptoid sequence and 
cyclizing it, that the potency of the antimicrobial peptoid is increased.26 Therefore, cyclization of 
the most potent trimers developed herein could potentially improve their activity although 
cyclization of peptoid trimers is somewhat challenging.27  
  
Section 4.2: Dimers with aromatic backbone. 
 
There is literature precedent that linear dimer peptoids can display low micromolar 
antimicrobial activity against a range of bacterial strains.14 Therefore, a range of peptoid dimers 
were designed (Figure 4.7) using similar side chains as those used with trimer synthesis. 
Cationic, aliphatic and aromatic residues were added to a similar backbone. However, here we 
are looking at whether an aromatic component of the backbone increases the lipophilicity and 
potency of the peptoid. The cationic portion of each dimer structure also has either: 1) a primary 
and secondary amine; or 2) two primary and a tertiary amine. The resulting antimicrobial activity 
of this peptoid class will also shed light on the importance of multiple positively charged groups 


























(C6) (C8) (C12)(Ph) (2Ph)(NH2) (2NH2)
 
Figure 4.7. Design and structure of the structurally rigid backbone peptoid dimers synthesized in 
this work. 
 
To test whether the positioning of the aliphatic chain—in relation to the aromatic 
backbone—plays an important role in antimicrobial activity, peptoid 25 was also synthesized 


















Figure 4.8. Representative structures of peptoid dimers with aromatic ring incorporated into 
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backbone for increased rigidity. 
 
Section 4.3: Peptoid Trimers with Aromatic Backbone via Solution-Phase Synthesis. 
 
Hypothetically, a monomeric peptoid or aromatic peptoid structure could also be 
envisioned, illustrated with an aromatic residue in Figure 4.9A. Preventing dialkylation is 
difficult, however, and therefore choosing stoichiometry to intentionally select for dialkylation 
was decided as the most optimal approach (Figure 4.9B). These structures also enable densely 
concentrating substantial hydrophobicity and cationic charge without the need for a large portion 
of the molecular weight to contain a peptidic backbone which is not thought to contribute to the 
membrane-lysing effects. Additionally, in contrast to all published examples of antimicrobial 
peptoids which utilize primary amines as cationic side chains, these peptoids utilize tertiary 




Figure 4.9. A) Comparison of backbone structures for aromatic backbone peptoids with 
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traditional peptide and peptoid backbones. B) Synthetic scheme showing that once the primary 
amine (R2-NH2) is reacted to form the secondary amine, the secondary amine will react further 
with the starting material. 
 
These aromatic backbone peptoid trimers were synthesized as described above in the 
methods section, starting from commercially available chloromethylbenzoyl chloride and N,N-
diethylethylenediamine to make 26. The subsequent addition of 0.5 equivalents of the desired 
amine in the presence of 1 equivalent of both 26 and KI, yielded the desired products 27-31 in 
decent yields. The synthetic route to these structures was not optimized to achieve better yield 
















































Scheme 4.2. Synthesis of structurally rigid-backbone peptoid trimers. Reagents and conditions: 




Two additional peptoids were synthesized, p-[({[p-
(hexylamino)carbonylphenyl]methyl}[2-
(diethylamino)ethyl]amino)methyl]phenyl}formaldehyde (32) and p-[({[p-
(phenethylamino)carbonylphenyl]methyl}[2-
(diethylamino)ethyl]amino)methyl]phenyl}formaldehyde (33) (Figure 4.10), for comparison 














Figure 4.10. Two aromatic backbone peptoid sequences designed to evaluate the importance of 
residue order as well as hydrophobicity (32 is an analog of 27, 33 is an analog of 30). 
 
Conclusions 
In summary, the rise of multi-drug resistant bacteria is an alarming issue and 
antimicrobial peptoids provide an ideal scaffold for the enhancement of activity against various 
bacterial strains. The experiments performed here have demonstrated that it is possible to achieve 
successful peptoid coupling using 1-minute coupling times versus the traditional 30 minutes to 3 
hours used by other researchers. Additionally, the rational design of these structures will allow 
for the further investigation of the impact of side-chain selection, peptoid length, and backbone 
rigidity on the effectiveness of short, linear antimicrobial peptoids. The ease of synthesis for 
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these short peptoid structures will enable the quantitative structure activity relationship analysis 
to develop predictive models for improved activity.  
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 The field of peptidomimetics is important in medicinal chemistry and aims to develop 
peptide analogues that retain (or enhance) biological activity yet possess more drug-like 
properties such as increased protease stability, improved bioavailability, enhanced membrane 
permeability, and other pharmacological parameters. Peptidomimetics encompass various 
modifications such as the incorporation of unnatural amino acids (e.g. PEG-amino acids), 
backbone modifications (e.g. peptoids), proline-mimetics as turn inducers (e.g. Freidinger 
lactams), and many other variations. The work presented in this dissertation builds upon the 
existing knowledge in the peptidomimetic field by: i) introducing pre-PEGylated amino acids 
(linear and branched) that can be easily incorporated into SPPS to yield peptides with site-
specific PEGylation; ii) the development of a novel synthetic route to obtain Freidinger-like 
lactams with incorporated chirality off the -nitrogen; and iii) the development of a library of 
short peptoids with potential antimicrobial activities.   
  The usage of the pre-PEGylated amino acids, such as those developed herein (i.e. chapter 
two), will enable researchers the ability to screen for the most optimal site of PEGylation within 
any sequence; using a PEG-scan approach—similar to how an alanine scan is used to determine 
residues important for peptide activity. These pre-PEGylated amino acids (glutamine, 
asparagine, and lysine) can be incorporated site-specifically as demonstrated in this work (i.e. 
chapter three) and provide novel conjugation strategies for PEG attachment to the side-chain of 
amino acids. The lysine PEGylation strategy developed in this work allows for the side-chain 
amine (N) to become positively charged under physiological conditions as opposed to the 
traditional PEGylation strategy that converts amines into amides; a strategy that does not allow 
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the original side-chain amine to continue participation in structure stabilizing salt-bridges or 
potential pi-cation interactions.  
 The novel synthetic route to Freidinger-like lactams that was developed in this work (i.e. 
chapter three) will expand the toolbox of reactions used by synthetic and medicinal chemistry 
researchers to get to these desired frameworks. If chiral amino acids (e.g. - or -amino acids, 
such as L-alanine or a chiral unnatural amino acid) are used in the synthesis instead of the model 
chiral amine used here, (S)-(-)-phenylethylamine, then the lactam product can be incorporated 
into a synthetic peptide of interest to introduce a conformational constraint. The ability to 
incorporate a variety of chiral groups off the -nitrogen can have an unpredictable effect on the 
modulation of pharmacological parameters and will be dependent on factors such as (but not 
limited to): i) the R-group that is attached at the chiral carbon adjacent to the -nitrogen; ii) any 
intramolecular interactions the R-group has with neighboring residues; and iii) the sequence and 
solution conformation(s) of the peptide. 
 The library of rationally-designed short peptoids developed herein (i.e. chapter four) need 
screening against various bacterial strains before structure activity relationships can be 
established. However, a display of low micromolar or better (i.e. nanomolar) antimicrobial 
activity by any of the peptoid structures against bacterial strains will generate lead compounds 






























APPENDIX A  
(PREPEGYLATED AMINO ACIDS) 
Data shown in this section were collected to help identify the desired products and purity of 
samples.   
 
NMR and MALDI Spectra 
General.  Column chromatography was performed on silica gel 60, particle size 0.040-0.063 
mm.  1H and 13C NMR spectra were recorded on either a Bruker (300 MHz or 500 MHz) or 
JEOL spectrometer (500 MHz). Thin-layer chromatography (TLC) was performed using silica 
gel precoated aluminum backed plates (200 m thickness). 1H NMR and 13C NMR were 
recorded in either CDCl3, MeOH-d4, (CH3)3CO-d6, or (CH3)3SO-d6. 
1H NMR spectra are 
reported as  in units of parts per million (ppm) with the solvent resonance as the internal 
standard. 13C NMR spectra are reported as  in units of ppm relative to the signal of CDCl3, 
MeOH-d4, (CH3)3CO-d6, or (CH3)3SO-d6. 13C NMR spectra were recorded with complete proton 
decoupling. Mass of samples were analyzed by either MALDI mass spectrometry or high-
resolution mass spectrometry using ESI. 
 








 To a stirring solution of Fmoc-Glu(OtBu)-OH (4 g, 9.401 mmol) and Na2CO3 (4.98 g, 
47.00 mmol) in DCM (50 mL) was added 2-bromoacetophenone (2.06 g, 10.34 mmol).   
Reaction mixture stirred for 18-70 h at room temperature (22-27 oC).  Reaction diluted with 
water and organic layer isolated.  Organic layer washed with saturated sodium carbonate (2 x) 
followed by a brine wash.  Organic layer dried over sodium sulfate, filtered, and concentrated.  
Desired product purified by flash chromatography using silica powder.  Dichloromethane (200 
mL), 1.5% MeOH/DCM (400 mL), and 5% MeOH/DCM (200 mL) used as eluents.  Product 
isolated as a solid (4.626 g, 90.5% yield). 
 
Analytical Data –  
 
1H NMR (300 MHz, Chloroform-d) δ 7.95 – 7.85 (m, 1H), 7.81 – 7.71 (m, 1H), 7.68 – 7.56 (m, 
2H), 7.55 – 7.23 (m, 4H), 5.66 (d, J = 8.1 Hz, 1H), 5.53 (d, J = 16.4 Hz, 1H), 5.31 (d, J = 16.3 
Hz, 1H), 4.58 (td, J = 8.1, 4.7 Hz, 1H), 4.41 (td, J = 11.4, 11.0, 7.2 Hz, 1H), 4.39 – 4.18 (m, 1H), 






Figure A-1. 1H NMR spectrum for Fmoc-Glu(OtBu)-OPac. 
 
13C NMR (126 MHz, CHLOROFORM-D) δ 191.38, 172.47, 171.72, 156.15, 144.04, 143.84, 
141.40, 141.38, 134.14, 134.06, 129.03, 127.84, 127.79, 127.78, 127.18, 125.28, 125.23, 120.06, 
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 Fmoc-Glu(OtBu)-OPac dissolved in TFA:H2O (3:1) v/v mixture and stirred 3 h at room 
temperature (22-27 oC).  Saturated aqueous sodium bicarbonate added to neutralize the acid.  The 




Analytical Data –  
 
1H NMR (500 MHz, DMSO-d6) δ 8.63 (d, J = 6.8 Hz, 1H), 7.97 (d, J = 7.7 Hz, 2H), 7.89 (d, J = 
7.5 Hz, 2H), 7.75 – 7.60 (m, 3H), 7.56 (t, J = 7.7 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.34 (td, J = 
7.4, 4.1 Hz, 2H), 5.56 (d, J = 16.9 Hz, 1H), 5.46 (d, J = 16.8 Hz, 1H), 4.27 – 4.16 (m, 4H), 2.19 
(t, J = 7.6 Hz, 2H), 2.15 – 2.05 (m, 1H), 1.97 – 1.85 (m, 1H). 
 
 




13C NMR (500 MHz, DMSO) δ 192.97, 174.23, 172.26, 156.59, 144.25, 144.19, 141.17, 134.49, 
134.20, 129.39, 128.26, 128.11, 127.55, 125.71, 120.59, 67.32, 66.22, 53.46, 47.07, 40.78, 40.50, 
40.23, 39.95, 39.67, 39.39, 39.22, 39.11, 30.30, 26.67. 
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 A stirring solution of tri(ethylene glycol)monomethyl ether (0.65 mL, 4.5 mmol) and N, 
N-diisopropylethylamine (0.86 mL, 4.95 mmol) in DCM (12 mL) was cooled to 0 oC.  To the 
stirring solution was added methane sulfonyl chloride (0.38 mL, 4.95 mmol) via syringe.  The 
reaction mixture was stirred for 1.5 h at 0 oC.  The reaction transferred to a separatory funnel and 
washed with brine (100 mL).  Organic phase concentrated under reduced pressure.  The residue 
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was partitioned between hexanes and H2O in separatory funnel.  Aqueous phase was isolated and 
NaCl (2 g) was added and agitated vigorously to dissolve the salt.  The solution was extracted 
with DCM (50 mL x 3).  The organic layers were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to yield a yellow oil (1.08 g, quantitative yield). 
 
A solution of TEGME-OMs (1 g, 4.38 mmol) and sodium azide (3.42 g, 52.56 mmol) in 
H2O (14 mL) and MeOH (5 mL) was stirred in a glass vial at reflux for 4 h, during which time 
the methanol was evaporated.  The aqueous phase was extracted with DCM (8 mL x 4).  Organic 
layers combined, dried over MgSO4, and concentrated to yield crude TEGME-N3 (430 mg, 







Figure A-7. 1H NMR spectrum for TEGME-N3. Solvent: CDCl3. 
 


















 TEGME-N3 (5 g, 28.5 mmol) was dissolved in dry THF (100 mL).  This solution was 
added dropwise to a stirring suspension of LiAlH4 (2.37 g, 62.5 mmol) in THF (50 mL).  The 
reaction was stirred for 2 h at room temperature under N2 (g).  The reaction was cooled to 0 
oC 
and a stream of N2 (g) was placed over the reaction mixture.  A small amount of MeOH was 
added very slowly, followed by the addition of small portions of H2O.  Solvent was vacuum 
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filtered from the solid inorganic byproducts.  An additional filtration through filter paper yielded 




1H NMR (500 MHz, Chloroform-d) δ 3.32 (pd, J = 5.4, 4.6, 2.6 Hz, 6H), 3.25 – 3.21 (m, 4H), 




Figure A-9. 1H NMR spectrum for TEGME-NH2. 
 















 Carbonyldiimidazole (CDI) (0.458 g, 2.822 mmol) was added to a suspension of Fmoc-
Glu(OH)-OPac in DCM (5 mL).  Solution was then poured slowly into a roundbottom containing 
TEGME-NH2 (0.421 g, 2.822 mmol) in DCM.  The reaction allowed to stir for 1.5 h.  The 
organic layer washed with saturated sodium bicarbonate (1 x), 0.10 M HCl (1 x), H2O (1 x), and 
brine (1 x).  The organic layer dried over sodium sulfate, decanted, and concentrated to yield 




1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 7.7 Hz, 3H), 7.74 (d, J = 7.5 Hz, 3H), 7.65 – 
7.56 (m, 4H), 7.47 (t, J = 7.7 Hz, 3H), 7.41 – 7.35 (m, 3H), 7.30 (tt, J = 7.5, 1.5 Hz, 3H), 5.67 (d, 
J = 8.2 Hz, 1H), 5.51 (d, J = 16.3 Hz, 1H), 5.29 (d, J = 16.3 Hz, 1H), 4.60 (t, J = 6.8 Hz, 1H), 
4.39 (d, J = 7.2 Hz, 2H), 4.21 (t, J = 7.0 Hz, 1H), 3.82 – 3.44 (m, 10H), 3.37 (s, 2H), 2.60 (t, J = 





Figure A-11. 1H NMR spectrum for Fmoc-Gln(mTEG)1-OPac.   
 
13C NMR (126 MHz, CHLOROFORM-D) δ 191.43, 171.58, 156.22, 143.98, 141.42, 
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Figure A-13.  MALDI-MS spectrum for Fmoc-Gln(mTEG)1-OPac. Calculated m/z = 








Fmoc-Glu(mTEG)1-OPac was dissolved in MeOH with stirring at room temperature. Mg 
granules (7 equiv.) were added, followed by AcOH (12 equiv.). The reaction mixture allowed to 
stir for 16 h. The reaction was concentrated in the presence of silica powder and dry loaded onto 
a silica column. The crude product was purified by column chromatography on silica gel using 
dichloromethane-methanol (0-20% methanol in dichloromethane) as eluent to obtain desired 




1H NMR (500 MHz, Chloroform-d) δ 7.71 (dd, J = 15.5, 8.2 Hz, 2H), 7.58 (q, J = 10.7, 9.1 Hz, 
2H), 7.44 – 7.17 (m, 5H), 4.40 – 3.99 (m, 3H), 3.69 – 3.30 (m, 12H), 3.26 (d, J = 16.1 Hz, 3H), 





Figure A-14. 1H NMR spectrum for Fmoc-Gln(mTEG)1-OH. 
 
13C NMR (126 MHz, CDCl3) δ 174.00, 156.58, 144.15, 143.88, 141.14, 127.58, 127.10, 125.30, 
119.79, 77.29, 77.23, 77.16, 77.03, 76.78, 71.78, 71.67, 70.21, 70.08, 69.86, 69.61, 66.77, 58.85, 







































Figure A-16.  MALDI-MS spectrum for Fmoc-Gln(mTEG)1-OH. Calculated m/z = 515.57 
















To a solution of TEGME-OMs (12 g, 49.527 mmol) in dry ACN (40 mL) was added benzyl 
amine (2.16 mL, 19.811 mmol). Sodium carbonate (6.3 g, 59.432 mmol) dissolved in water (10 
mL) and added to the reaction mixture. The reaction was heated to reflux and stirred for 72 h. 
The organic layer was concentrated and the crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol (0-20% methanol in 
dichloromethane) as eluent to obtain desired product. Desired fractions combined and 
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Figure A-17.  MALDI-MS spectrum for N-Benzyl-(mTEG)2-Amine. Calculated m/z = 













To a solution of N-Benzyl-(mTEG)2-Amine (1.21 g, 3.021 mmol) in MeOH (50 mL) was added 
Pd/C (0.161 g, 1.511 mmol) with stirring. The roundbottom was evacuated and subsequently 
filled with H2(g). The reaction was stirred at room temperature for 18 h. The reaction mixture 
was filtered through a bed of celite before concentrating the solvent to yield crude product (0.892 
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Figure A-18.  MALDI-MS spectrum for (mTEG)2-Amine. Calculated m/z = 310.22 
















































Propylphosphonic anhydride (T3P) was added to a solution of Fmoc-Glu(OH)-OPac in a mixture 
of DCM and ACN. To the solution was added (mTEG)2-NH in DCM. The reaction was stirred 
for 1.5 h. The organic layer was concentrated and the crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol (0-20% methanol in 
dichloromethane) as eluent to obtain desired product. Desired fractions combined and 





1H NMR (500 MHz, Acetone-d6) δ 8.01 (d, J = 7.7 Hz, 2H), 7.85 (d, J = 7.5 Hz, 2H), 7.70 (dt, J 
= 23.9, 7.3 Hz, 3H), 7.56 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 
5.62 (d, J = 16.6 Hz, 1H), 5.47 (d, J = 16.6 Hz, 1H), 4.50 (dd, J = 9.2, 5.1 Hz, 1H), 4.34 (dt, J = 
7.0, 3.2 Hz, 2H), 4.24 (t, J = 7.2 Hz, 1H), 4.01 – 3.35 (m, 23H), 3.32 – 3.23 (m, 6H), 3.14 (s, 
1H), 2.62 (d, J = 7.7 Hz, 2H), 2.39 – 2.30 (m, 1H), 2.14 (dt, J = 14.4, 7.4 Hz, 1H), 2.10 – 2.03 






Figure A-20. 1H NMR spectrum for Fmoc-Gln(mTEG)2-OPac.  
 
13C NMR (126 MHz, ACETONE-D6) δ 205.47, 205.33, 205.32, 205.31, 205.16, 192.00, 141.29, 
133.86, 128.95, 127.84, 127.72, 127.16, 125.37, 119.99, 71.87, 70.31, 70.24, 70.16, 66.71, 66.47, 
57.99, 54.34, 47.19, 29.77, 29.62, 29.58, 29.48, 29.42, 29.39, 29.33, 29.27, 29.17, 29.14, 29.12, 
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Figure A-22.  MALDI-MS spectrum for Fmoc-Gln(mTEG)2-OPac. Calculated m/z = 
779.70 [M+H]+, 801.70 [M+Na]+, 817.70 [M+K]+. Observed m/z = 799.22 [M+Na]+, 







Fmoc-Glu(mTEG)2-OPac was dissolved in AcOH with stirring at room temperature. Mg 
granules (7 equiv.) was added. The reaction mixture allowed to stir for 16 h. The reaction was 
concentrated and dry loaded onto silica column. The crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol (0-20% methanol in 
dichloromethane) as eluent to obtain desired product. Desired fractions combined and 
concentrated to yield desired product.  
 
Analytical Data 
1H NMR (500 MHz, Methanol-d4) δ 7.82 – 7.77 (m, 2H), 7.67 (p, J = 5.5, 4.4 Hz, 2H), 7.38 (tt, J 
= 6.4, 2.4 Hz, 2H), 7.31 (tdt, J = 7.4, 3.6, 1.8 Hz, 2H), 4.36 (dtd, J = 20.7, 6.8, 4.4 Hz, 2H), 4.26 
– 4.18 (m, 1H), 3.64 – 3.44 (m, 27H), 3.37 – 3.33 (m, 5H), 2.62 – 2.51 (m, 1H), 2.38 (dt, J = 






Figure A-23. 1H NMR spectrum for Fmoc-Gln(mTEG)2-OH.  
 
13C NMR (126 MHz, Methanol-d4) δ 175.07, 174.06, 173.83, 157.37, 143.87, 141.29, 127.49, 
126.88, 124.98, 119.64, 72.34, 71.59, 70.21, 70.03, 69.91, 69.18, 68.86, 66.69, 66.57, 60.90, 









Figure A-25.  MALDI-MS spectrum for Fmoc-Gln(mTEG)2-OH. Calculated m/z = 












 To a stirring solution of Fmoc-Glu(OH)-OPac and H2N-CH2CH2-NHBoc in ACN was 
added T3P and DIEA. The reaction was stirred for 16 h at room temperature (22-27 oC). The 
crude product was purified by column chromatography on silica gel using dichloromethane-







1H NMR (300 MHz, Chloroform-d) δ 7.97 – 7.88 (m, 2H), 7.78 (d, J = 7.5 Hz, 2H), 7.64 (dd, J = 
7.6, 3.5 Hz, 3H), 7.53 (t, J = 7.5 Hz, 2H), 7.47 – 7.24 (m, 6H), 6.63 (s, 1H), 5.95 (s, 1H), 5.62 (d, 
J = 16.5 Hz, 1H), 5.39 – 5.26 (m, 2H), 5.17 (s, 1H), 4.54 (d, J = 6.7 Hz, 1H), 4.44 (d, J = 7.1 Hz, 
2H), 4.25 (t, J = 6.9 Hz, 1H), 3.30 (s, 3H), 2.43 (s, 2H), 2.22 (d, J = 6.8 Hz, 1H), 1.71 (s, 1H), 
1.39 (s, 11H). 
 
 








 To a stirring solution of Fmoc-Glu(OH)-OPac and H2N-CH2CH2-NHBoc in DMF was 
added EDC and DIEA. The reaction was stirred for 18 h at room temperature (22-27 oC). The 
crude product was purified by column chromatography on silica gel using dichloromethane-
methanol (0-5% methanol in dichloromethane) as eluent to obtain desired product. 
Analytical Data 
 
1H NMR (500 MHz, Chloroform-d) δ 7.87 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.59 
(ddt, J = 7.1, 5.1, 2.5 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.41 – 7.32 (m, 1H), 7.29 (ddd, J = 7.7, 
4.7, 1.5 Hz, 1H), 5.84 (d, J = 8.1 Hz, 0H), 5.49 (d, J = 16.3 Hz, 0H), 5.29 (d, J = 16.3 Hz, 0H), 
4.58 (q, J = 7.6 Hz, 0H), 4.36 (d, J = 7.2 Hz, 1H), 4.21 (t, J = 7.3 Hz, 1H), 3.86 (s, 5H), 3.19 – 
3.08 (m, 1H), 2.70 (d, J = 14.9 Hz, 1H), 2.63 – 2.53 (m, 1H), 2.37 (dd, J = 13.9, 6.6 Hz, 0H), 



















 To a solution of Nα-Fmoc-Nε-Boc-Lys-OH and bromoacetophenone in DCM was added a 
solution of sodium carbonate and tetrabutylammonium bromide in H2O and reaction was stirred 
at room temperature (22-27 oC) for 16-72 h.  Organic layer washed with water, and then 
concentrated.  Desired product purified by flash chromatography on silica gel using 
dichloromethane-methanol (0-20% methanol in dichloromethane) as eluent to obtain desired 
product.   
 




1H NMR (500 MHz, Chloroform-d) δ 7.93 – 7.87 (m, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.66 – 7.57 
(m, 3H), 7.48 (t, J = 7.8 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.31 (td, J = 7.4, 1.3 Hz, 2H), 5.58 – 
5.51 (m, 1H), 5.26 (d, J = 16.3 Hz, 1H), 4.90 (s, 1H), 4.54 (td, J = 7.8, 5.2 Hz, 1H), 4.40 (qd, J = 
10.6, 7.1 Hz, 2H), 4.23 (t, J = 7.1 Hz, 1H), 3.17 (d, J = 8.3 Hz, 2H), 2.03 (ddd, J = 15.0, 9.4, 5.1 
Hz, 1H), 1.89 (s, 1H), 1.60 – 1.48 (m, 3H), 1.43 (s, 9H). 
 
 
Figure A-28. 1H NMR spectrum for Fmoc-Lys(NHBoc)-OPac.  
 
13C NMR (126 MHz, Chloroform-d) δ 191.67, 172.11, 156.30, 156.12, 144.02, 143.85, 141.40, 
141.38, 134.22, 133.98, 130.08, 129.03, 127.88, 127.80, 127.18, 125.24, 120.08, 120.06, 79.13, 










Figure A-30.  MALDI-MS spectrum for Fmoc-Lys(NHBoc)-OPac. Calculated m/z = 






 Fmoc-Lys(NHBoc)-OPac dissolved in TFA:DCM (3:1 v/v) and stirred at room 
temperature (22-27 oC) for 2 h.  The solvent was evaporated under a stream of N2 (g) to yield 
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crude Fmoc-Lys(NH2)-OPac. Complete conversion to product monitored by MALDI mass 
spectroscopy.  
 
 To a stirring solution of tri(ethyleneglycol)monomethyl ether (TEGME or mTEG) in 
DCM at 0 oC was added trifluorosulfonic anhydride ((Tf)2O) dropwise.  Solution stirred for 5-10 
mins before adding it to the crude solution of Fmoc-Lys(Boc)-OPac in DCM at 0 oC.  The 
reaction was stirred for 1 h at 0 oC before evaporating the solvent under a stream of N2 (g). The 
crude product was purified by column chromatography on silica gel using dichloromethane-
methanol (0-20% methanol in dichloromethane) as eluent to obtain desired product. 
 
Analytical Data –  
 
1H NMR (300 MHz, DMSO-d6) δ 8.01 – 7.94 (m, 2H), 7.90 (dd, J = 8.0, 4.2 Hz, 4H), 7.72 (dt, J 
= 10.6, 5.3 Hz, 5H), 7.57 (t, J = 7.5 Hz, 3H), 7.47 – 7.38 (m, 5H), 7.37 – 7.30 (m, 4H), 5.71 – 
5.40 (m, 1H), 4.50 – 4.04 (m, 2H), 3.85 – 3.40 (m, 36H), 3.22 (s, 9H), 1.97 (d, J = 9.4 Hz, 0H), 





Figure A-31. 1H NMR spectrum for Fmoc-Lys(mTEG)3-OPac.  
 
13C NMR (75 MHz, DMSO) δ 192.91, 172.38, 156.63, 144.25, 144.17, 141.20, 134.54, 134.18, 
129.40, 128.24, 128.11, 127.52, 125.68, 120.60, 79.86, 79.42, 78.98, 71.72, 70.18, 69.99, 69.94, 
67.23, 66.17, 64.13, 60.39, 59.23, 58.50, 55.36, 54.04, 47.10, 40.80, 40.69, 40.53, 40.25, 39.97, 
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Figure A-33.  MALDI-MS spectrum for Fmoc-Lys(mTEG)3-OPac. Calculated m/z = 






 Fmoc-Lys(mTEG)3-OPac was dissolved in AcOH with stirring at room temperature 
followed by the addition of Mg granules.  The reaction was stirred for 1 h.  Magnesium was 
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filtered from the reaction mixture and the AcOH evaporated under vacuum. The crude product 
was purified by column chromatography on silica gel using dichloromethane-methanol (0-20% 




1H NMR (300 MHz, DMSO-d6) δ 7.88 (d, J = 7.4 Hz, 2H), 7.69 (s, 2H), 7.41 (t, J = 7.4 Hz, 3H), 
7.31 (t, J = 7.4 Hz, 3H), 4.43 – 4.09 (m, 1H), 4.03 (s, 0H), 3.76 (s, 2H), 3.61 (s, 3H), 3.53 – 3.34 
(m, 18H), 3.20 (q, J = 2.8, 1.7 Hz, 8H), 1.63 (s, 2H), 1.21 (s, 2H).  
 
 




13C NMR (126 MHz, Acetone) δ 205.45, 205.29, 205.13, 204.94, 137.95, 128.86, 127.20, 
121.13, 119.77, 107.98, 71.78, 70.05, 69.98, 64.45, 59.82, 59.70, 57.96, 33.02, 29.70, 29.61, 
29.51, 29.41, 29.36, 29.26, 29.20, 29.11, 29.05, 28.95, 28.89, 28.80, 28.71, 28.65, 28.52, 28.49. 
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Figure A-36.  MALDI-MS spectrum for Fmoc-Lys(mTEG)3-OH. Calculated m/z = 



































 Fmoc-Lys(NHBoc)-OH was dissolved in TFA:DCM (3:1) v/v with stirring at room 
temperature (22-27 oC).  The reaction mixture was stirred for 2 h.  The reaction was diluted with 
DCM and neutralized with saturated aqueous sodium carbonate.  The organic layer was isolated 
and concentrated.   
 
A solution of oxalyl chloride (0.24 mL, 2.714 mmol) in dry DCM (20 mL) prepared and 
cooled in dry ice/acetone under N2 (g) and stirred for 15 mins.  DMSO (0.29 mL, 4.071 mmol) in 
dry DCM was added and stirred at -78 oC for 20 mins.  TEGME (0.062 mL, 0.385 mmol) was 
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added slowly and the reaction mixture stirred for 30 mins.  Triethylamine (1.14 mL, 8.142 
mmol) added slowly over 1 min and the reaction mixture was stirred for 30 mins at -78 oC before 
warming to room temperature (22-27 oC) slowly.  The reaction mixture was concentrated under a 
stream of N2 (g).  
 
 A solution of Fmoc-Lys(NH2)-OH (600 mg, 1.629 mmol) with crude TEGME-aldehyde 
was prepared in ACN (20 mL) and stirred.  Solid NaCNBH3 (0.256 g, 4.071 mmol) was added to 
the stirring reaction and allowed to stir for 18 h at room temperature (22-27 oC).  The reaction 
was quenched with 0.012 M HCl, followed by the addition of brine, and DCM.  The organic 
layer was separated and concentrated to yield 1.95 g of crude material. The crude product was 
purified by column chromatography on silica gel using dichloromethane-methanol (0-10% 




1H NMR (500 MHz, CDCl3) 
1H NMR (500 MHz, Chloroform-d) δ 9.30 (s, 1H), 7.65 (d, J = 7.4 
Hz, 3H), 7.55 (t, J = 8.0 Hz, 2H), 7.31 – 7.26 (m, 3H), 7.24 – 7.18 (m, 2H), 4.31 – 4.16 (m, 3H), 
4.12 (t, J = 7.2 Hz, 1H), 3.78 (t, J = 5.1 Hz, 2H), 3.67 – 3.37 (m, 20H), 3.29 – 3.25 (m, 2H), 3.24 





Figure A-37. 1H NMR spectrum for Fmoc-Lys(mTEG)2-OH.  
 
13C NMR (126 MHz, CHLOROFORM-D) δ 202.80, 172.88, 156.34, 143.90, 143.83, 141.24, 
127.73, 127.23, 127.15, 125.32, 125.28, 124.90, 119.93, 85.23, 77.56, 77.30, 77.05, 72.56, 72.55, 
71.93, 71.85, 71.83, 71.79, 71.61, 71.05, 71.02, 70.93, 70.77, 70.69, 70.66, 70.51, 70.40, 70.38, 
70.35, 70.21, 70.20, 70.16, 70.14, 70.05, 66.98, 65.93, 61.52, 61.46, 58.96, 58.88, 58.87, 53.83, 
52.46, 47.58, 47.18, 47.13, 46.16, 46.02, 45.88, 40.90, 31.42, 26.81, 25.40, 22.60, 22.51, 8.85, 
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 To a solution of TEGME (0.87 mL, 5.427 mmol) in DCM at 0 oC was added 
trifluoromethanesulfonic anhydride (0.93 mL, 5.562 mmol) and allowed to stir for 3 mins. The 
reaction mixture was transferred portion-wise to a solution of Fmoc-Lys(NH2)-OPac (1.32 g, 
2.713 mmol) and DIEA (0.47 mL, 2.713 mmol) in DCM (20 mL) at 0 oC and stirred for 20 mins. 
The reaction mixture was concentrated under reduced pressure to yield crude material. The crude 
product was purified by column chromatography on silica gel using dichloromethane-methanol 
(0-6% methanol in dichloromethane) as eluent to obtain product. The desired fractions were 







Figure A-40. 1H NMR spectrum for Fmoc-Lys(mTEG)2-OPac.  
 
13C NMR (126 MHz, CHLOROFORM-D) δ 143.99, 143.87, 141.41, 134.18, 134.03, 129.05, 
127.80, 127.18, 125.16, 120.05, 71.89, 71.89, 70.43, 70.30, 66.60, 65.99, 58.98, 53.84, 52.72, 




































































 A solution of Fmoc-Lys(mTEG)2-OPac (628 mg, 0.806 mmol) was dissolved in 4% 
pyridine in acetonitrile (50 mL) and stirred.  Zn dust (420 mg, 6.419 mmol) and acetylacetone 
(1.33 mL, 12.84 mmol) added to the stirring reaction and heated to 85 oC. The reaction mixture 
was stirred for 5 h at 85 oC.  The reaction was filtered to removed undissolved Zn dust.  The 
filtrate was concentrated under reduced pressure to yield crude material. The crude product was 
purified by column chromatography on silica gel using dichloromethane-methanol (0-10% 
methanol in dichloromethane) as eluent to obtain product. The desired fractions were combined 






Figure A-43. 1H NMR spectrum for Fmoc-Lys(mTEG)2-OH. PH6011. 
 
13C NMR (126 MHz, CHLOROFORM-D) δ 144.04, 143.94, 141.35, 129.17, 127.76, 127.18, 
125.27, 124.42, 120.40, 120.01, 71.83, 70.41, 70.27, 66.99, 65.46, 58.96, 58.87, 54.20, 52.78, 
47.22, 31.33, 23.90, 22.69, 21.81, 19.70, 13.59. 
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 Fmoc-Lys(NHBoc)-OH (0.763 g, 1.629 mmol) was dissolved in TFA:DCM (3:1) v/v 
with stirring at room temperature (22-27 oC).  The reaction mixture was stirred for 2 h.  The 
reaction was diluted with DCM and neutralized with saturated aqueous sodium carbonate.  The 
organic layer was isolated and concentrated to yield crude Fmoc-Lys(NH2)-OH.   
 Method A:  A solution of oxalyl chloride (0.24 mL, 2.714 mmol) in dry DCM (20 mL) 
prepared and cooled in dry ice/acetone under N2 (g) and stirred for 15 mins.  DMSO (0.29 mL, 
4.071 mmol) in dry DCM was added and stirred at -78 oC for 20 mins.  TEGME (0.062 mL, 
0.385 mmol) was added slowly and the reaction mixture stirred for 30 mins.  Triethylamine (1.14 
mL, 8.142 mmol) added slowly over 1 min and the reaction mixture was stirred for 30 mins at -
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78 oC before warming to room temperature (22-27 oC) slowly.  The reaction mixture was 
concentrated under a stream of N2 (g).  
 A solution of crude Fmoc-Lys(NH2)-OH (600 mg, 1.629 mmol) with crude TEGME-
aldehyde was prepared in ACN (20 mL) and stirred.  Solid NaCNBH3 (0.256 g, 4.071 mmol) 
was added to the stirring reaction and allowed to stir for 18 h at room temperature (22-27 oC).  
The reaction was quenched with 0.012 M HCl, followed by the addition of brine, and DCM.  The 
organic layer was separated and concentrated to yield 1.95 g of crude material. The crude 
product was purified by column chromatography on silica gel using dichloromethane-methanol 




1H NMR (500 MHz, Chloroform-d) δ 11.27 (s, 1H), 9.33 (s, 1H), 7.68 (d, J = 7.4 Hz, 2H), 7.57 
(t, J = 8.0 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.25 (dt, J = 7.5, 3.8 Hz, 2H), 6.11 (d, J = 8.0 Hz, 
1H), 4.35 – 4.19 (m, 3H), 4.15 (t, J = 7.2 Hz, 1H), 3.81 (t, J = 5.0 Hz, 2H), 3.61 – 3.50 (m, 8H), 
3.44 (q, J = 6.3, 3.9 Hz, 3H), 3.31 – 3.28 (m, 1H), 3.26 (s, 3H), 2.94 (q, J = 7.3, 6.8 Hz, 2H), 




Figure A-46. 1H NMR spectrum for Fmoc-Lys(mTEG)1-OH.  
 
13C NMR (126 MHz, Chloroform-d) δ 173.80, 172.83, 156.29, 143.88, 143.83, 143.81, 141.15, 
127.65, 127.09, 125.28, 125.24, 119.85, 77.70, 77.44, 77.21, 77.19, 72.48, 72.46, 71.84, 71.74, 
71.53, 70.41, 70.24, 70.13, 70.06, 70.05, 69.99, 66.84, 65.83, 61.34, 61.29, 58.78, 58.72, 53.69, 
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Figure A-48.  MALDI-MS spectrum for Fmoc-Lys(mTEG)1-OH. Calculated m/z = 





 To a stirring solution of Fmoc-Lys(mTEG)1-OH (200 mg, 0.388 mmol) in tBuOH (10 
mL) was added DIEA (0.35 mL, 1.943 mmol). Subsequently, Boc2O (0.53 mL, 2.332 mmol) was 
added and the reaction mixture was stirred at room temperature (22-27 oC) for 72 h. The solvent 
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was evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using 30% EtOAc (in hexane), 60% EtOAc (in hexane), then 
dichloromethane-methanol (0-2% methanol in dichloromethane) as eluent to obtain product. The 














Figure A-49. 1H NMR spectrum for Nα-Fmoc-Nε-Boc-Lys(mTEG)1-OH. 
 
13C NMR (126 MHz, Chloroform-d) δ 172.94, 172.43, 156.08, 155.99, 143.95, 143.77, 141.33, 
127.72, 127.09, 125.12, 120.00, 79.12, 71.92, 70.61, 70.58, 70.55, 68.89, 67.02, 66.97, 64.40, 
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Figure A-51.  MALDI-MS spectrum for Nα-Fmoc-Nε-Boc-Lys(mTEG)1-OH. Calculated 







APPENDIX B  
(PEPTIDES) 
Data shown in this section (HPLC, MALDI-MS, CD) were collected to help identify the desired 
products, purity of samples, and/or -helical content.   
 
General 
Synthesis.  Manual synthesis was used to couple Fmoc amino acids (8 equiv), applying 
2-chlorotrityl chloride resin (1.11 mmol/g loading) or rink amide resin (0.5 mmol/g loading) and 
standard DIC/6-Cl-HOBt activation. Coupling of mTEGylated amino acids to a growing peptide 
sequence was extended from our typical 5-minute coupling time up to 10 minutes. 
Sample calculation for amount of PEG amino acid (AA) to use during Fmoc SPPS (8 
equiv. PEG AA): 0.1 g (amount of resin) * 0.5 mmol/g (resin loading) * 1 mol/1000 mmol 
(conversion factor) * 8 mol AA/1 mol resin * 514.58 g/mol (MW of Fmoc-Gln(mTEG)1-OH) = 
206 mg needed for peptide synthesis.  
Cleavage.  Cleavage of the peptides from the resin and global deprotection was 
performed in trifluoroacetic acid/triisopropylsilane/water (90:5:5). Subsequently, concentration 
in vacuo, precipitation with diethyl ether, and purification by preparative reversed-phase (C18) 
HPLC yielded the mPEGylated peptides in pure form. We did not observe -elimination products 
of the peptides, nor any truncations due to insufficient coupling of building blocks 12, 13, 16, 
and 19.  
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Yield Calculation.  Theoretical yield of peptides were calculated following the following 
formula: Theoretical yield = resin loading capacity (mmol/g) * amount of resin used (g) * 
conversion factor (1 mol/1000 mmol) * molecular weight of peptide (g/mol). Sample calculation: 
0.5 mmol/g * 0.1 g * 1053 g/mol * 1 mol/1000 mmol = 0.0526 g = 52.6 mg (100% theoretical 
yield). A 20% yield of peptide from this sample calculation would yield 21 mg.  
Peptide Concentration Measurements. Concentrations of stock solutions of peptides 
were determined by UV absorbance. The UV absorbance method involved measuring the 
absorbance of peptides containing tryptophan in 0.15 M NaCl, pH 7.0, and then calculating the 
molar concentration from 280nm = 5590 M
-1 cm-1 for tryptophan peptides. 
Circular Dichroism Measurements. CD measurements were made using an JASCO 
J810 spectropolarimeter. Measurements were made in a 1.0-cm quartz cell in 0.15 M NaCl, 0 oC, 
pH 7. CD measurements are reported as mean residue ellipticity at a given wavelength of peptide 
samples and as molar ellipticity for tryptophan model compounds; all measurements are reported 








Figure B-1. MALDI spectrum of Lypressin (L8VP).  Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Lys-Gly-NH2. Calculated m/z = 1057.23 [M+H]






Figure B-2. Analytical HPLC data for crude Lypressin (L8VP).  Sample was injected 
onto a C18 analytical column (4.6 mm x 10 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-95% acetonitrile in 
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Figure B-3. MALDI spectrum of mTEG1 Gln
4-L8VP.  Cys-Tyr-Phe-Gln(PEG)1-Asn-Cys-Pro-
Lys-Gly-NH2. Calculated m/z = 1203.42 [M+H]
+. Observed m/z (crude sample) = 1204.87 





Figure B-4.1.  Analytical HPLC data for purified mTEG1 Gln
4-L8VP.  Sample was 
injected onto a HASIL C18 analytical column (100 mm x 4.6 cm) and eluted using 
isocratic solution of 5% acetonitrile in water for 2 minutes, followed by a linear gradient 
of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 
minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient 
of 40-95% over 8 minutes. Desired product elutes at ~11.5 minutes. Cys-Tyr-Phe-
Gln(mTEG)1-Asn-Cys-Pro-Lys-Gly-NH2. 
 
Datafile Name:TH21 24m frac1.lcd
Sample Name:TH21 24m frac 
Sample ID:TH21 24m frac




































Figure B-4.2.  Analytical HPLC data for purified mTEG1 Gln
4-L8VP. Sample was 
injected onto a C18 analytical column (250 x 10 mm) and eluted using isocratic solution 
of 5% acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 
minutes, a linear gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear 









Figure B-5.  MALDI spectrum of PEG2 Gln
4-L8VP.  Cys-Tyr-Phe-Gln(mTEG)2-Asn-
Cys-Pro-Lys-Gly-NH2. Calculated m/z = 1349.60 [M+H]
+. Observed m/z = 1350.84 




Datafile Name:TH14 29.5m frac 1.lcd
Sample Name:TH14 29.5m frac 
Sample ID:TH14 29.5m frac 
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Figure B-6.  Analytical HPLC data for purified PEG2 Gln
4-L8VP. Sample was injected 
onto a C18 analytical column (250 x 10 mm) and eluted using isocratic solution of 5% 
acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 minutes, a linear 
gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear gradient of 40-95% over 









Figure B-7.  MALDI spectrum of PEG Lys4-L8VP.  Cys-Tyr-Phe-Lys(mTEG)3-Asn-
Cys-Pro-Lys-Gly-NH2. Calculated m/z (with disulfide bond) = 1495.83 [M]
+. Calculated 
















































Figure B-8.  PEG Lys4-L8VP.  Cys-Tyr-Phe-Lys(mTEG)3-Asn-Cys-Pro-Lys-Gly-NH2. 
Description: HAISIL 100 C18 5 m. Dimensions: 100 x 4.6 mm. Particle size: 5 m. 
Pore size: 80angstroms. Mobile phase 5-95% Acetonitrile in Water. Flow Rate: 1 
mL/min. Temp: 25 oC. Injection: 10 L. Desired products elutes at ~2.5-3.5 minutes. 








Figure B-9.  MALDI spectrum of mTEG Lys8-L8VP.  Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Lys(mTEG)3-Gly-NH2. Calculated m/z (with disulfide bond) = 1494.78 [M]
+. Calculated 




 Datafile Name:TH10 30.1m frac 1.lcd
Sample Name:TH10 30.1m frac 
Sample ID:TH10 30.1m frac 
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Figure B-10.  Analytical HPLC data for purified mTEG3 Lys
8-L8VP.  Sample was 
injected onto a C18 analytical column (250 x 10 mm) and eluted using isocratic solution 
of 5% acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 
minutes, a linear gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear 























































Figure B-11.  mTEG Lys8-L8VP.  Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys(mTEG)3-Gly-
NH2. Description: HAISIL 100 C18 5 m. Dimensions: 100 x 4.6 mm. Particle size: 5 
m. Pore size: 80 angstroms. Mobile phase 5-95% Acetonitrile in Water. Flow Rate: 1 
mL/min. Temp: 55 oC. Injection: 10 L. Desired product elutes at ~8 min. Peptide was in 







Figure B-12.  MALDI spectrum of (mTEG)3-Asn
5-Lypressin. Cys-Tyr-Phe-Gln-Asn 
(mTEG)3-Cys-Pro-Lys-Gly-NH2. Calculated m/z (with disulfide bond)= 1537.76 [M]
+. 


















Figure B-14.  MALDI-MS of crude peptide.  
HAEGTFTSDVSSYLEGQ(mTEG)AAKEFIAWLVKGR. Calculated m/z = 3444.88. 
Observed m/z = 3446.757. 
 
 
Figure B-15.  RP-HPLC profile of crude GLP-1(Q23) 7-36 amide.  
HAEGTFTSDVSSYLEGQ(mTEG)AAKEFIAWLVKGR.  Wavelength = 254 nm.  
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Injection volume = 20 μL.  0-100% ACN over 10 mins.  100% ACN from 10-20 mins.  
Purity = 54.7% 
 
 
Figure B-16.  MALDI-MS of GLP-1(Q9) 7-36 amide.  
HAQ(mTEG)GTFTSDVSSYLEGQAAKEFIAWLVKGR.  Calculated m/z = 3443.89. 






Figure B-17.  RP-HPLC profile of GLP-1(Q9) 7-36 amide.  
HAQ(mTEG)GTFTSDVSSYLEGQAAKEFIAWLVKGR.  Wavelength = 254 nm.  
Injection volume = 15 μL.  0-100% ACN over 10 mins.  100% ACN from 10-20 mins.  





Figure B-18.  RP-HPLC of control solution.  Wavelength = 254 nm.  Injection volume = 
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Figure B-19.  MALDI-MS of crude peptide.  Ac-WG(EAAAK)3A-NH2. Calculated m/z 













































Figure B-20.  Analytical HPLC of crude peptide.  Ac-WG(EAAAK)3A-NH2. Calculated 
m/z = 1784.99. Observed m/z = 1783.263. Sample was injected onto a C18 analytical 
column (150 mm x 4.6 mm) and eluted using isocratic solution of 5% acetonitrile in 
water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water (constant 
0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% 
over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. Desired 
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Figure B-21.  MALDI-MS of crude peptide.  Ac-





















































Figure B-22. Analytical HPLC of crude peptide.  Ac-
WGEAAAKEAAAK(mTEG)3EAAAKA-NH2. Calculated m/z = 2224.56. Observed m/z 
= 2221.769. Sample was injected onto a C4 analytical column (150 mm x 2.1 cm) and 
eluted using isocratic solution of 5% acetonitrile in water for 2 minutes, followed by a 
linear gradient of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% 
acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, 
























































Figure B-23. Analytical HPLC of crude peptide.  Ac-
WGEAAAKEAAAK(mTEG)3EAAAKA-NH2. Calculated m/z = 2224.56. Observed m/z 
= 2221.769. Sample was injected onto a C18 analytical column (150 mm x 4.6 mm) and 
eluted using isocratic solution of 5% acetonitrile in water for 2 minutes, followed by a 
linear gradient of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% 
acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, 
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Figure B-24.  MALDI-MS of crude peptide.  Ac-
WGEAAAKEAAAK(mTEG)2EAAAKA-NH2. Calculated m/z = 2077.37. Observed m/z 
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Figure B-25.  MALDI-MS of crude peptide.  Ac-
WGEAAAKEAAAK(mTEG)1EAAAKA-NH2. Calculated m/z = 1931.18. Observed m/z 















































Figure B-26.  Analytical HPLC of crude peptide.  Ac-
WGEAAAKEAAAK(mTEG)1EAAAKA-NH2. Calculated m/z = 1931.18. Observed m/z 
= 1928.993. Sample was injected onto a C18 analytical column (150 mm x 4.6 mm) and 
eluted using isocratic solution of 5% acetonitrile in water for 2 minutes, followed by a 
linear gradient of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% 
acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, 





Figure B-27. Preliminary dichroic spectra of the peptides 
AcWGEAAAKEAAAKEAAAKA-NH2 (TH23 unmodified, 72.4% -helix), 
AcWGEAAAKEAAAK(mTEG)1EAAAKA-NH2 (TH25 monoPEG, 2.1% -helix), 
AcWGEAAAKEAAAK(mTEG)2EAAAKA-NH2 (TH25 diPEG, 31.9% -helix), and 
AcWGEAAAKEAAAK(mTEG)3EAAAKA-NH2 (TH24 triPEG, 19.3% -helix). Peptide 
concentrations were 30 M (except diPEG 6.7M). All solvents contained 150 mM NaCl, 





APPENDIX C  
(LACTAM SYNTHESIS) 
Data shown in this section were collected to help identify the desired products and purity of 
samples.   
 
NMR and MALDI Spectra 
General.  Column chromatography was performed on silica gel 60, particle size 0.040-0.063 
mm.  1H and 13C NMR spectra were recorded on either a Bruker (300 MHz or 500 MHz) or 
JEOL spectrometer (500 MHz). 
 
Figure C-1. 1H NMR comparison of crude product mixture from diazotization attempt on 5-
aminovalericacid at 5 equiv NaBr/2 equiv NaNO2 (Top) and 10 equiv NaBr/5 equiv NaNO2 
(Bottom). Reagents and conditions: a) NaNO2, NaBr, 16% HBr, 0






Figure C-2. 1H NMR of crude product mixture from diazotization of -alanine at 5 equiv 
NaBr/2 equiv NaNO2 (Top) and 10 equiv NaBr/5 equiv NaNO2 (Bottom). Reagents and 
conditions: a) NaNO2, NaBr, 16% HBr, 0
oC, 1 h. 
 
 
Scheme C-1. Attempt to remove Boc and perform diazotization yielded no removal of Boc and 
no desired product.  Starting material recovered. (PH0019, PH0021) reagents and conditions: a) 
5 eq NaNO2, 20 eq NaBr, 48% HBr,TFA,  -6 
oC to r.t. or 3 eq NaNO2, 10 eq NaBr, 2.5M H2SO4, 
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Synthesis of Product X (Unknown product from attempted diazotization and subsequent 
reaction with Nspe). 
Procedure 
 
 Fmoc-Orn(NH2)-OH and NaBr were dissolved in 16-48% HBr with stirring at 0 
oC.  A 
solution of NaNO2 was added slowly to the stirring reaction mixture. The reaction was stirred for 
1 h.  The reaction was diluted with EtOAc and the organic layer separated.  The aqueous layer 
was extracted twice more with EtOAc and the organic layers were combined, dried over sodium 
sulfate, and concentrated.  
 
 The crude product was dissolved in dry ACN and Nspe was added.  The reaction mixture 
allowed to stir for 18 h at room temperature.  The solvent was concentrated and the crude 




Scheme C-2. Proposed synthetic route with protection of carboxylic acid as a methyl ester.  
Reagents and conditions: a) T3P, MeOH, 27.3%. b) 3:1 (v/v) TFA:DCM. c) 5 eq NaNO2, 20 eq 
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Figure C-3. IR spectrum of Product X. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.81 – 7.77 (m, 1H), 7.66 – 7.57 (m, 3H), 7.53 (ddd, J = 
8.1, 3.1, 1.8 Hz, 2H), 7.42 – 7.33 (m, 2H), 7.29 (dtd, J = 8.6, 4.1, 1.8 Hz, 3H), 3.92 (t, J = 6.3 
Hz, 1H), 3.81 (q, J = 6.6 Hz, 1H), 3.08 (dd, J = 12.2, 5.8 Hz, 1H), 2.86 (dd, J = 12.2, 6.8 Hz, 








Figure C-4. 1H NMR spectrum for Product X. Top – full spectrum. Bottom – expanded region 




13C NMR (126 MHz, CDCl3) δ 147.83, 147.78, 145.34, 139.31, 139.21, 133.13, 130.54, 130.48, 
128.70, 128.60, 128.52, 128.47, 128.35, 128.14, 128.07, 127.05, 126.71, 125.90, 121.24, 121.17, 



















Predicted Spectra.  
 
 
































 To a stirring solution of Fmoc-Glu(OtBu)-OH (2.0 g, 4.7 mmol) and DIEA (1.64 mL, 9.4 
mmol) in allyl bromide (15 mL) was prepared. The reaction mixture was heated to reflux for 1 h. 
Upon cooling, the resulting reaction mixture was poured into EtOAc (200 mL) and the 
precipitated DIEA-HCl was filtered. The filtrate was washed with 0.01 M HCl (1 x), saturated 
aqueous sodium bicarbonate (1 x), and then with water (1 x). The organic layer containing crude 
Fmoc-Glu(OtBu)-OAll was isolated dried over sodium sulfate, filtered, and concentrated.   
 The crude product was dissolved in TFA:DCM (20 mL, 1:1, v/v) with stirring at room 
temperature for 1.5 h. The reaction was concentrated to yield crude Fmoc-Glu(OH)-OAll.  
The crude Fmoc-Glu(OH)-OAll was dissolved in DCM (50 mL) and DIEA (0.55 g) 
added. A subsequent addition of CDI (1.03 g) was made and the reaction mixture was stirred for 
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10 min. (S)-(-)-phenylethylamine was added and the reaction mixture was stirred for 30 min. The 
reaction mixture was concentrated under reduced pressure. 
Desired product purified by flash chromatography on silica gel using dichloromethane-
methanol (0-5% methanol in dichloromethane) as eluent to obtain desired product. The desired 
fractions were combined and concentrated. The product was isolated as a pale yellow solid (1.87 
g, 77.6% yield over 3 steps). 
 
Analytical Data –  
 
 
Figure C-10. 1H NMR spectrum for Fmoc-Gln(Nspe)-OAll. 
 
13C NMR (126 MHz, CHLOROFORM-D) δ 171.81, 170.90, 156.48, 143.99, 143.72, 143.24, 
141.41, 141.38, 131.49, 128.76, 127.82, 127.46, 127.18, 126.31, 125.86, 125.21, 120.08, 119.42, 
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 To a stirring solution of Fmoc-Glu(Nspe)-OAll (50 mg, 0.10 mmol) in DCM (3 mL) at 0 
oC was added trifluoromethanefulfonic anhydride (0.02 mL, 0.11 mmol). The reaction mixture 
stirred for 30 min. The reaction was brought to room temperature (20 oC) before diluting with 
THF (6 mL). To the stirring reaction mixture was added NaBH4 (5 mg, 0.13 mmol). The reaction 
was stirred for 1 h at room temperature before quenching with water. The desired product 
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 A solution of Fmoc-Orn(Nspe)-OAll (0.57 g, 1.143 mmol), DIEA (0.25 mL, 2.286 
mmol), and NaHCO3 (0.066 g, 0.057 mmol) in DMF (20 mL).  The reaction mixture was 
brought to 90 oC and stirred for 18 h. The reaction was diluted with water and DCM. The organic 
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Figure C-14.  MALDI-MS spectrum for (R)-3-[(R)-1-Phenylethyl]-2-
oxocyclohexylamino (9H-fluoren-9-yl)acetate from preliminary text reaction. Calculated 





APPENDIX D  
(PEPTOIDS) 
Data shown in this section (HPLC, MALDI-MS, NMR) were collected to help identify the 
desired products and purity of peptoid samples.   
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Figure D-1. Top - MALDI spectrum of 1. Calculated m/z = 434.00 [M+H]+. Observed m/z 
= 432.75 [M+H]+. Bottom – Analytical HPLC of crude 1. Sample was injected onto a C4 
analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% acetonitrile 
in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water 
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(constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 
20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. 

































































































Figure D-2. Top - MALDI spectrum of 2. Calculated m/z = 461.65. Observed m/z = 460.782 
[M+K]+. Bottom – Analytical HPLC of crude 2. Sample was injected onto a C4 analytical 
column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% acetonitrile in water for 2 
minutes, followed by a linear gradient of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 
minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 
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Figure D-3. Top - MALDI spectrum of 3. Calculated m/z = 517.76, 557 [M+K]+. 
Observed m/z = 516.59 [M+H]+. MC26. Bottom – Analytical HPLC of crude 3. Sample 
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was injected onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic 
solution of 5% acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a 
linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% 




















































































Figure D-4. MW = 462.64. Top - MALDI spectrum of 4. Calculated m/z = 463.64 
[M+H]+. Observed m/z = 461.68 [M+H]+. Bottom – Analytical HPLC of crude 4. Sample 
was injected onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic 
solution of 5% acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, 
a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-
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Figure D-5. Top - MALDI spectrum of 5. Calculated m/z = 491.69 [M+H]+. Observed 
m/z = 489.697 [M+H]+. Bottom – Analytical HPLC of crude 5. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
 
 278 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 























































Figure D-6. Top - MALDI spectrum of 6. Calculated m/z = 547.80 [M+H]+. Observed m/z 
= 545.63 [M+H]+. Bottom – Analytical HPLC of crude 6. Analytical HPLC data for crude 
peptoid.  Sample was injected onto a C4 analytical column (150 mm x 2.1 cm) and eluted 
using isocratic solution of 5% acetonitrile in water for 2 minutes, followed by a linear 
gradient of 5-20% acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% 
acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, 
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Figure D-7. Top - MALDI spectrum of 7. Calculated m/z = 524.73 [M+H]+, 562.73 [M+K]+. 
Observed m/z = 522.623 [M+H]+, 560.485 [M+K]+. Bottom – Analytical HPLC of crude 7. 
Sample was injected onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic 
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solution of 5% acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a 
linear gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 












































Figure D-8. MW = 551.78. Top - MALDI spectrum of 8. Calculated m/z = 552.78 [M+H]+. 
Observed m/z = 550.54 [M+H]+. Bottom – Analytical HPLC of crude 8. Sample was injected 
onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water 
(constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% 
over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. Desired product 
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Figure D-9. MW = 607.46. Top - MALDI spectrum of 9. Calculated m/z = 608.46 [M+H]+. 
Observed m/z = 606.49 [M+H]+. Bottom – Analytical HPLC of crude 9. Sample was injected 
onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
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acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water 
(constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% 
over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. Desired product 
















Figure D-10. Top - MALDI spectrum of 10. Calculated m/z = 553.77 [M+H]+. 575.7 [M+Na]+. 
Observed m/z = 551.60 [M+H]+. Bottom – Analytical HPLC of crude 10. Sample was injected 
onto a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water 
(constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% 
over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. Desired product 



















































































Figure D-11. Top - MALDI spectrum of 11. Calculated m/z = 581.82 [M+H]+. Observed 
m/z = 579.53 [M+H]+. Bottom – Analytical HPLC of crude 11. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
minutes. Desired product elutes at ~16 minutes. 
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Figure D-12. Top - MALDI spectrum of 12. Calculated m/z = 637.93 [M+H]+. Observed 
m/z = 635.45 [M+H]+. Bottom – Analytical HPLC of crude 12. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
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acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
































































































































































Datafile Name:MC37 25.7m frac 1.lcd
Sample Name:MC37 25.7m frac 
Sample ID:MC37 25.7m frac 
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Figure D-13. Top - MALDI spectrum of crude 15. Calculated m/z = 349.49 [M+H]+. 
Observed m/z = 348.09 [M+H]+. Bottom – Analytical HPLC of purified 15. Sample was 
injected onto a C18 analytical column (250 x 10 mm) and eluted using isocratic solution 
of 5% acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% 
acetonitrile in water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 
minutes, a linear gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear 
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Figure D-14. Top - MALDI spectrum of 16. Calculated m/z = 377.55 [M+H]+. Observed 
m/z = 376.05 [M+H]+. Bottom – Analytical HPLC of crude 16. Sample was injected onto 
a C18 analytical column (250 x 10 mm) and eluted using isocratic solution of 5% 
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acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 minutes, a linear 
gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear gradient of 40-95% over 
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Figure D-15. Top - MALDI spectrum of 17. Calculated m/z = 433.65 [M+H]+. Observed 
m/z = 431.87 [M+H]+. Bottom – Analytical HPLC of crude 17. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
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acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 

























































































































































Figure D-16. Top - MALDI spectrum of 18. Calculated m/z = 369.48 [M+H]+. Observed 
m/z = 368.02 [M+H]+. Bottom – Analytical HPLC of crude 18. Sample was injected onto a 
C18 analytical column (250 x 10 mm) and eluted using isocratic solution of 5% acetonitrile 
in water for 3 minutes, followed by a linear gradient of 5-20% acetonitrile in water 
(constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 minutes, a linear gradient of 
20-40% over 10 minutes, 40% for 4 minutes, a linear gradient of 40-95% over 16 minutes. 
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Figure D-17. Top - MALDI spectrum of 19. Calculated m/z = 459.61 [M+H]+. Observed 
m/z = 457.68 [M+H]+. Bottom – Analytical HPLC of crude 19. Sample was injected onto 
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a C18 analytical column (250 x 10 mm) and eluted using isocratic solution of 5% 
acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 minutes, a linear 
gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear gradient of 40-95% over 


































































Figure D-18. Top - MALDI spectrum of 20. Calculated m/z = 378.53 [M+H]+. Observed 
m/z = 377.77 [M+H]+. Bottom – Analytical HPLC of crude 20. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
































































































Figure D-19. Top - MALDI spectrum of 21. Calculated m/z = 406.59 [M+H]+. Observed m/z = 
 
 300 
403.93 [M+H]+. Bottom – Analytical HPLC of crude 21. Sample was injected onto a C4 
analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% acetonitrile in 
water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in water (constant 0.1% 
TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear gradient of 20-40% over 5 
minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 minutes. Desired product elutes 
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Figure D-20. Top - MALDI spectrum of 22. Calculated m/z = 462.70 [M+H]+. Observed 
m/z = 460.80 [M+H]+. Bottom – Analytical HPLC of crude 22. Sample was injected onto 
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a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
















































































































Figure D-21. Top - MALDI spectrum of 23. Calculated m/z = 398.25 [M+H]+. Observed 
m/z = 396.88 [M+H]+. Bottom – Analytical HPLC of purified 23. Sample was injected 
onto a C18 analytical column (250 x 10 mm) and eluted using isocratic solution of 5% 
acetonitrile in water for 3 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 12 minutes, 20% acetonitrile for 4 minutes, a linear 
gradient of 20-40% over 10 minutes, 40% for 4 minutes, a linear gradient of 40-95% over 
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Figure D-22. Top - MALDI spectrum of 24. Calculated m/z = 488.65 [M+H]+. Observed 
m/z = 486.52 [M+H]+. Bottom – Analytical HPLC of crude 24. Sample was injected onto 
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a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 






































































Figure D-23. MALDI spectrum of 27. Calculated m/z = 566.85 [M+H]+. Observed m/z = 
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Figure D-24. MALDI spectrum of 31. Calculated m/z = 594.90 [M+H]+. Observed m/z = 


























































































Figure D-25. Top - MALDI spectrum of 28. Calculated m/z = 651.01 [M+H]+. Observed 












































































































200 300 400 500 600 700 800
m/z  
 
Figure D-26. Top - MALDI spectrum of 30. Calculated m/z = 586.84 [M+H]+. Observed 














































































Figure D-27. Top - MALDI spectrum of 29. Calculated m/z = 676.96 [M+H]+. Observed 
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Figure D-28. Top - MALDI spectrum of 25. Calculated m/z = 378.53 [M+H]+. Observed 
























































































Figure D-29. Top - MALDI spectrum of 13. Calculated m/z = 463.64 [M+H]+. Observed 
m/z = 461.76 [M+H]+. Bottom – Analytical HPLC of crude 13. Sample was injected onto 
a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
minutes. Desired product elutes at ~12.5 minutes. 
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Figure D-30. Top - MALDI spectrum of 14. Calculated m/z = 637.93 [M+H]+. Observed 
m/z = 635.49 [M+H]+. Bottom – Analytical HPLC of crude 14. Sample was injected onto 
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a C4 analytical column (150 mm x 2.1 cm) and eluted using isocratic solution of 5% 
acetonitrile in water for 2 minutes, followed by a linear gradient of 5-20% acetonitrile in 
water (constant 0.1% TFA) over 3 minutes, 20% acetonitrile for 2 minutes, a linear 
gradient of 20-40% over 5 minutes, 40% for 2 minutes, a linear gradient of 40-95% over 8 
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Figure D-31. Top - MALDI spectrum of 32. Calculated m/z = 551.83 [M+H]+. Observed 
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Figure D-32. Top - MALDI spectrum of 33. Calculated m/z = 591.81 [M+H]+. Observed 






LIST OF SYMBOLS AND ABBREVIATIONS 
SPPS     Solid phase peptide synthesis 
ΔG*     Gibbs free energy 
NMR     Nuclear magnetic resonance 
PPM     Parts per million 
TEGME (mTEG)   Tri(ethyleneglycol) monomethyl ether 
COSY     Correlation spectroscopy 
NOESY    Nuclear Overhauser effect spectroscopy 
EDA     Ethylene diamine 
NOE     Nuclear Overhauser effect 
TLC     Thin layer chromatography 
DCM     Dichloromethane 
AcOEt     Ethyl acetate 
MeOH     Methanol 
AcOH     Acetic Acid 
AcAc     Acetylacetone 
Py     Pyridine 
Lys     Lysine 
Gln     Glutamine 
Glu     Glutamic acid 
Asn     Asparagine 
Asp     Aspartic acid 
T3P     Propylphosphonic anhydride 
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NHS     N-hydroxysuccinimide 
TEMPO    (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl 
Bipy     2,2’-Bipyridine 
DIEA     Diisopropylethyl amine 
DMF     N,N-Dimethyl formamide 
OPac     Phenacyl ester 
NaCNBH3    Sodium cyanoborohydride 
NaBH4     Sodium borohydride 
CDI     Carbonyldiimidazole 
DCC     N,N’-Dicyclohexylcarbodiimide 
DIC     N,N’-Diisopropylcarbodiimide 
EDC     1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
6-Cl-HOBt    1-Hydroxy-6-chloro-benzotriazole 
HCTU O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate 
TFA     Trifluoroacetic acid 
Tf2O     Triflic anhydride 
  
 
